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Abstract
Cytochrome P450 enzymes play a vital role in the safe elimination of 
foreign compounds, such as drugs and toxins, from the human body. 
They are responsible for increasing the hydrophilicity of a compound 
to allow for effective excretion through the kidneys, a process known 
as Phase I metabolism. Given the importance of this metabolism for 
the safe excretion of a foreign compound, cytochrome P450 enzymes 
have long been of interest to the pharmaceutical drug industry.
Currently, animal testing provides one of the most effective ways of 
determining the safe metabolism of a drug compound, however there 
are still problems. The cytochrome P450 2D family has only one 
form in humans, GYP2D6, responsible for the metabolism of %20% 
of drugs in current clinical use, but six forms in rats, GYPs 2D1-2D5 
and GYP 2D 18. This makes it difficult to determine if a drug will be 
safely eliminated in humans based on rat studies alone, as shown by 
the isomers quinine and quinidine. Despite having similar chemical 
structures, these isomers show a variation in potency. By identifying 
the underlying cause of this species selectivity it may be possible to 
earlier identify which compounds show the most promise in humans 
saving the pharmaceutical industry both time and money.
Using computational techniques, models of the rat cytochrome P450 
2D enzymes have been produced based on the recent x-ray crystal 
structures of the human cytochrome P450 2D6 enzyme both with 
and without a ligand bound. The differences in species selectivity for 
isomers, such as quinidine and quinine, are rationalised using these
models and the results are discussed with regard to previous studies. 
Models were generated under the CHARMM27 force field to more ac­
curately model the haem iron.
Molecular docking studies are performed for quinidine and quinine 
into both the haem and compound 1 forms of the rat and human 
CYP2D family. In this case, no one amino acid residue is identi­
fied as responsible for the variation in inhibition observed for these 
compounds but rather a change in the number of binding interactions 
occuring. This is consistent with molecular recognition in cytochrome 
P450 enzymes being the result of a number of non-specific interactions 
in a binding site.
A preliminary investigation into the effect that docking topology has 
on ligand function in rat and human CYP2D enzymes suggests a rela­
tionship between the orientation angle of the docked compound rela­
tive to the haem iron. In the majority of cases inhibitors are found to 
dock parallel to the haem group and substrates normal to the haem. 
In a virtual screen of seven substrates and eight inhibitors into both 
the haem and compound 1 forms, an overall agreement with this hy­
pothesis of 58% and 66% was found for models based on the crystal 
structure of human CYP2D6 with a ligand bound and without respec­
tively. Substrates were correctly predicted 38% of the time for models 
based on the crystal structure with ligand bound and 42% of the time 
for models based on the crystal structure without. Inhibitors were 
predicted correctly in 78% of cases for models based on the ligand 
bound structure and for 85% of cases based on the structure without. 
In a virtual screen of a validation set of forty substrates and inhibitors, 
ligands were correctly predicted 58% and 55% of the time for models 
based on the structure with and without a ligand bound respectively. 
This suggests that for cytochrome P450 enzymes, potent substrates 
and inhibitors can be identified at an early stage of drug development
through placement analysis within the active site regardless of species 
or stereochemistry.
The more potent isomer from quinidine and quinine is defined as the 
compound with an orientation angle closest to an ideal inhibitor an­
gle of 90°. Quinidine is predicted to be the more potent isomer for 
rat CYP2D5 for which no experimental information currently exists, 
while quinine is predicted to be more potent in rat CYP2D18.
Using sequence analysis, three amino acid residues (residues 209, 210 
and 388) are identified which are predicted to impact the species se­
lectivity of isomers as observed for quinidine and quinine in rat and 
human CYP2D enzymes. These residues are located both within and 
at some distance from the active site and are located near substrate 
recognition sites and access channels, suggesting that their mutation 
will have an affect on substrate and inhibitor access and product egress 
from the active site.
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Chapter 1
Introduction
Cytochrome P450 enzymes play a vital role in the human body’s metabolism of 
xenobiotic substrates, being responsible for the metabolism of %75% of drugs 
in current clinical use, and as such they have long been consider of the utmost 
importance to the pharmaceutical industry Traditionally animal models have 
been used to predict a drugs metabolism in vivo, with rats being one of the 
most common animal models used. However, there are questions regarding the 
transferablility of these models to humans. The cytochrome P450 2D (CYP2D) 
family, shows only one isoform in humans (CYP2D6) which is responsible for 
the metabolism of %20% of therapeutic drugs, while in rats six isoforms are ob­
served, CYPs 2D1-2D5 and CYP2D18. A key example of this problem of species 
difference is the effect of stereochemistry on the human cytochrome P450 2D6. 
The diastereoisomers quinidine and quinine (Figure 1.1) show a species selective 
response when metabolised by either rat or human.
Quinidine is observed to be a strong inhibitor of human CYP2D6 while qui­
nine, although having little effect on human CYP2D6 metabolism, is a strong 
inhibitor of rat CYP2D enzymes, especially rat CYP2D2 (Table 1.1).
The aim of this thesis is to try and identify the cause of this observed species 
selectivity in rat and human CYP2D enzymes.
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Figure 1.1: Structures of the isomers quinine and quinidine.
/  iiM
Ligand CYP2D1 CYP2D2 CYP2D3 CYP2D4 CYP2D6
Quinidine 19.9±1.9 2.8±0.7 26.94:4.4 47.24:13.4 0.00334:0.001
Quinine 46.5T7.6 0.0094±0.009 12.04:0.2 1.74:0.4 0.614:0.05
Table 1.1: Experimental /C 50 values =b the standard deviations in fiM  for quini­
dine and quinine in rat and human CYP2D enzymes taken from Venhorst et al. 
[1]-
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1.1 Cytochrome P450 Enzymes
The cytochrome P450 super family of haem-containing enzymes, so named for 
the characteristic absorption peak observed at 450 nm for the reduced carbon 
monoxide-complexed haem group [2, 3], is of great importance to metabolism 
and has long been the focus of much research. The superfamily is classified into a 
series of smaller families with a sequence homology of >40% and subfamilies with 
a homology of >55%. To date, more than 6000 CYPs have been identified in all 
species with humans possessing 18 families with 43 subfamilies and 57 functional 
GYP genes [4]. Of these 43 subfamilies, only five isoforms (CYPs 1A2 [5], 2C9 
[6], 2C19 [7], 2D6 [8, 9] and 3A4 [10]) are responsible for the vast majority of drug 
metabolism i.e. >75% of drugs in current clinical use [11]. There are a number 
of excellent reviews on the current state of cytochrome P450 research with work 
by Redic and Di Carlo [12] and Guengerich [13-16] providing a comprehensive 
background of the cytochrome P450 enzyme family.
1.1.1 Cytochrome P450 Structure
Despite the often low sequence similarity between cytochrome P450 enzymes, 
there is a high level of structural conservation with a small, predominantly (3- 
strand containing, N-terminal domain and a larger C-terminal domain consisting 
of both the haem and the active site . For all currently crystallised human CYPs 
(Figure 1.2), the same basic structure of 12 a-helical regions and 4 /5-sheets is ob­
served [5]. Overall, the active site region has the most structural similarity with 
the same helicies (D, E, I, L, J and K) and /5-sheets (4-1 and 4-2) surrounding 
the conserved haem group (Figure 1.3) [17].
Human CYP2D6, the focus of this work, like other cytochrome P450 enzymes, 
retains this characteristic protein fold. There are two available crystal structures 
of human CYP2D6; the 2F9Q structure [8] (which has no ligand bound in the 
active site) and the 3QM4 crystal structure [9] which has the inhibitor prinoma­
stat (Figure 1.4) bound to the haem.
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Figure 1.2: Sequence alignment showing the secondary structure of the five human 
cytochrome P450 isoforms reponsible for the metabolism of >75% of drugs in 
current clinical use (1A2 [5], 2C9 [6], 2C19 [7], 2D6 [8, 9] and 3A4 [10]). o-helices 
are shown in red, /3-sheets in yellow and /3-turns in blue.
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Figure F3: General topology of cytochrome P450 2D6 based on the available 
2F9Q [8] crystal structure of human CYP2D6 [18]. o-helices are shown in red, 
^-sheets in blue and /3-turns in green.
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Figure 1.4: Structure of prinomastat which is bound to the haem in the 3QM4 
crystal structure of human cytochrome P450 2D6.
The 3QM4 active site is 130Â^ larger than that of the 2F9Q crystal structure 
resulting in an active site cavity that more uniformly surrounds the haem group 
unlike the “right foot” cavity of 2F9Q [8, 9]. Overall the structures are reason­
ably similar with some changes observed in the position and orientation of amino 
acid residues due to the change in the active site. The most significant change 
observed in the ligand bound structure when compared to that of the 2F9Q struc­
ture is the formation of the F ’ helix (Figure 1.5). In 2F9Q this F ’ helix is part 
of a larger F helix (see Figure 1.3) resulting not only in significant variation in 
the side chain positions between the two structures but also the observation of 
a new substrate access channel running below the F ’ helix, above the haem and 
the K-^1-4 loop.
Both the 2F9Q and 3QM4 structures display a shortened G helix with a pre­
ceding G” helix that would normally be part of a longer G helix in other GYP2 
family enzymes.
Not unexpectedly, the inducible nature of cytochrome P450 enzymes allows 
the 3QM4 ligand bound crystal structure to show a distinctly different confor­
mation for the active site than that of the 2F9Q crystal structure with no ligand 
bound (Figure 1.6).
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Figure 1.5: General topology of cytochrome P450 2D6 based on the available 
3QM4 [9] crystal structure of human CYP2D6 [18]. o-helices are shown in red, 
/3-sheets in blue and /3-turns in green.
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Figure L6: Structural overlay showing the variation within the active site of the 
two available human CYP2D6 crystal structures. 2F9Q is shown in yellow and 
3QM4 is shown in blue.
Homology models of rat CYPs 2D1-2D5 and 2D18 were generated based on 
both the available 2F9Q [8] and 3QM4 [9] crystal structures (see Chapter 3).
1.1.1.1 Cytochrom e P450 Substrate Recognition and Access
Given the high structural similarity of cytochrome P450 enzymes, especially 
within subfamilies, and their versatility of metabolism, it is important to con­
sider not only how substrates and inhibitors gain access to the conserved active 
site but also how these substrates are identified.
Work by Wade et al [19] identified a series of access and egress channels 
within the cytochrome P450 enzyme family which would account for not only
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the movement of substrates and products both in and out of the active site but 
also any small molecules, such as water, that may be involved in catalysis. Five 
channels were identified in total along with a water and solvent access channel 
(Figure 1.7).
Channel 1 exists between the C /C ’ and H or L helicies close to the G-H helix 
loop.
Channel 2 is made up of a large family of subchannels lined by the B-G loop 
and B’ helix that can merge to form one large channel depending on the 
position of the F and G helicies.
Subchannel 2a is in the space between the F-G loop, the B’ helix, the B-B’ 
loop, the B-G loop and /3-sheets 1-1 and 1-2.
Subchannel 2b is between the B-B’ loop and /3-sheets 1-1, 1-2, 1-4 and 3-1.
Subchannel 2c is between helicies G and I and the B’ helix/B-G loop.
Subchannel 2ac is between 2a and 2c at the tip of the B-G loop and the 
G helix.
Subchannel 2d is between helicies A’/A  and the N-terminus.
Subchannel 2e goes through the B-G loop.
Subchannel 2f is between the F ’ helix, the F-G loop and ^-sheets 4-1 and 
4-2.
Channel 3 is between the F and G helicies and the E-F loop.
Channel 4 goes through the F-G loop.
Channel 5 is between the K and K’ helicies.
The Solvent Channel passes between helicies E, F and I and /3-sheets 3-3, 4-1,
4-2 and 3-2.
The Water Channel is at the base of the B-G loop and near the G-terminus of 
the B helix.
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Figure 1.7: Ail channels predicted by Wade et al. [19] shown in their theoretical 
positions in human CYP2D6 (2F9Q) [8].
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Wade et al. [19], as observed by Rowland et al. [8] in the 2F9Q crystal struc­
ture, shows only a single solvent channel for human CYP2D6. Wang et al. [9] 
however observed a second channel suggesting that other channels may form.
While these channels explain how substrates can access the active site of cy­
tochrome P450 enzymes it is important to consider how these substrates are 
identified for metabolism. Gotoh [20] suggests a series of substrate recognition 
sites identified in regions with high numbers of amino acid changes. In total 
six sites (Figures 1.8 and 1.9) were predicted in the CYP2 family with site 1 
(SRSl) being located at the B’ helix and the surrounding area (residues 100- 
125), site 2 (SRS2) at the C-terminal end of the F helix (residues 206-213), site 3 
(SRS3) at the N-terminal end of the G helix (residues 240-247), site 4 (SRS4) at 
the N-terminal half of the I helix (residues 294-312), site 5 (SRS5) surrounding 
^-sheet 1-4 (residues 367-378) and site 6 (SRS6) at yd-sheet 4-1 (residues 477-484).
These sites account for %15% of all positions in the GYP2 alignment and 
show greater structural fiexibility to allow for the metabolism of more varied 
compounds. Five of these sites (SRSl - SRS5) have been identified in the chan­
nel 2 family [19, 20] with SRSl being identified in most cases of the channel 2 
subfamily due to its location on the B’ helix (see Ghapter 6).
1.1.2 Cytochrome P450 M etabolism
Gytochrome P450 enzymes are responsible for the metabolism of %75% of drugs 
in current clinical use. They are capable of performing a wide variety of chemical 
reactions with the phase I mono-oxygenase activity being responsible for most 
drug metabolism [18, 21].
R -H  +  O2 +  NADPH +  H +   ^R -O H  -b H^O +  NADP+
While some GYP reactions do not require any outside infiuence to perform 
catalysis, the vast majority of reactions require an electron transfer from NADPH 
(Nicotinamide Adenine Dinucleotide Phosphate) [17, 21].
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Figure 1.8: Sequence showing the locations of the six substrate recognition sites 
identified by Gotoh [20] for all rat and human CYP2D enzymes. SRSl is shown 
in yellow, SRS2 in green, SRS3 in blue, SRS4 in purple, SRS5 in red and SRS6 
in dark green.
Figure 1.9: Locations of the six substrate recognition sites identified by Gotoh 
[20] in the 2F9Q crystal structure of human CYP2D6 [8]. SRSl is again shown 
in yellow, SRS2 in green, SRS3 in blue, SRS4 in purple, SRS5 in red and SRS6 
in dark green.
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Cytochrome P450 enzymes can be classified based on their electron transfer 
mechanism;
Class I requires both a FAD (Flavin Adenine Dinucleotide) containing reductase 
and iron sulfur redoxin.
Class II requires a FAD/FMN (Flavin Mononucleotide) containing CYP450 re­
ductase.
Class III is self-sufficient and requires no outside electron donor.
Class IV is a direct transfer of electrons from NADPH. [17, 21]
Human CYP2D6 is a Class II enzyme [22].
The highly conserved active site observed in CYP450 enzymes consists of a 
haem group with iron at the centre of a porphyrin ring. The iron ion exists in 
the octahedral conformation being coordinated to the four nitrogen atoms of the 
pyrrole subunits of the porphyrin, the sulfur of a local cysteine (Cys443) and has 
a sixth coordination site that is available for the binding of small extraneous lig­
ands. In the resting state this site is believed to be occupied by a water molecule 
with the iron in a low spin Fe(HI) state.
The catalytic cycle (Figure 1.10) for the phase 1 mono-oxygenase activity 
proceeds as follows;
1. The xenobiotic substrate (RH) displaces the water at the sixth coordination 
site causing a change to high-spin Fe(HI).
2. A one-electron reduction occurs to give the ferrous Fe(II) (the reducing elec­
tron originates from NADPH and is the defining step of a phase I metabolic 
action).
3. Molecular oxygen binds to form the ferrous-oxy intermediate which is in 
equilibrium with the ferric-superoxy intermediate.
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Figure 1.10: The catalytic cycle for cytochrome P450 mono-oxygenase activity. 
RH is the substrate and ROH is the hydroxylated product [18, 23].
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4. A second one-electron reduction occurs to give the ferric-peroxy species.
5. Protonation occurs to give the ferric-hydroperoxy intermediate, known as 
compound 0.
6. A second protonation step results in the breaking of the bound dioxygen 
giving the active oxidising species, known as compound 1.
7. Compound 1 attacks the nearby xenobiotic substrate to form the ferric 
complex and the hydroxylated xenobiotic substrate.
8. The hydroxylated product is released from the catalytic cycle for excretion 
and the haem iron catalyst returned to its original state [18].
It is likely that docking to the active oxidising species, compound 1, will pro­
vide more accurate docking predictions for enzyme substrates due to the limited 
conformational space available. Docking of both substrates and inhibitors has 
therefore been performed to both the ground-state haem group and the com­
pound 1 form (see Chapter 5).
1.1.3 Cytochrome P450 Substrates and Inhibitors
Generally CYP450 substrates and inhibitors show a similar underlying structure 
with a basic nitrogen located 5-7Â from the site of oxidation and a fiat aromatic 
region [24, 25] (Figure 1.11).
The basic nitrogen is predicted to interact with either an aspartic acid located 
on the I helix (AspSOl) or a glutamic acid located on the F helix (Glu216) while 
the aromatic region is predicted to interact with one of two aromatic phenylala­
nines, Phel20 (located on the B’-C loop) or Phe483 (on the /54-1-4-2 loop), and 
several other hydrophobic residues such as a leucine on the F helix (Leu213) and 
a valine on helix I (Val308) [26, 27]. There is extensive research into the impor­
tance of these residues to enzyme action with residues 301, 216 and 120 having 
long been considered to be important for cytochrome P450 activity [28].
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7.03
Figure 1.11: Common pharmacophore for CYP2D6 substrates based on the sub­
strate 5-Methoxytryptamine. Areas in green are areas of hydrophobicity, areas 
in orange represent aromaticity while the areas in purple show hydrogen bond 
donors and areas in blue are acceptors. As you can see the basic nitrogen is 7.03Â 
from the site of oxidation.
Nitrogen-containing ligands are more often inhibitors than substrates, replac­
ing the water in the sixth coordination site of the haem iron and stabilising the 
low spin Fe(III). This type II binding is characterised by a shift in the absorption 
peak to %430 nm [17, 29, 30]. Type I binding, often characteristic of substrates, 
displaces this water molecule shifting the iron into the high spin form and ac­
celerating CYP45Ü reduction. In this case the peak moves to %390 nm (Figure 
1.12) [17, 29, 30].
1.2 The Quinine\Quinidine Problem
The diastereomers quinidine and quinine (Figure 1.1) are well documented in­
hibitors of both rat and human cytochrome P450 enzymes, but despite their 
similarities they show dramatically different binding affinities. Quinidine, the 
prototypical inhibitor of human CYP2D6, is more than eight hundred times more 
inhibiting in human than in any rat CYP2D enzyme (Table 1.1). Quinine, how-
17
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Figure 1.12: The UV difference spectra obtained for the addition of a Type I or 
Type II binding ligand in cytochrome P450. The figure was taken from the TCM 
group [31] based on data from Omura et al. [32]
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ever, is six times more inhibiting in rat CYP2D than in human CYP2D6 and 
eighteen times more inhibiting of CYP2D2 than any other rat CYP2D enzyme.
It has been hypothesised by Venhorst et al. [1] that the increased inhibitory 
effect of quinidine in human CYP2D6 when compared to rat CYP2D enzymes 
is due to its closer proximity to the haem allowing a lone pair donation from 
the quinoline nitrogen to the iron, while the higher inhibition of quinine by rat 
CYP2D2 may be attributed to the observed hydrogen bond between the basic 
quinoline nitrogen and an aspartic acid residue (Asp216). Work by Hutzler et 
al. [33] however, suggests that hydrogen bonding of the hydroxyl group controls 
quinidine^s inhibitory potency rather than an interaction with the basic nitrogen. 
It is also suggested that the preferred binding orientations within the active site 
can affect potency. Quinidine shows a type I binding spectrum indicating a com­
petitive interaction while quinine has a type II binding spectrum indicating that 
the quinine is ligated to iron in the sixth coordination site (Figure 1.13) [33].
Residues 120, 216 and 301, commonly believed to be of great importance to 
cytochrome P450 activity, are shown in a work by Sutcliffe et. al [28] to have a sig­
nificant impact on quinidine binding. Their studies show an almost complete loss 
of quinidine inhibition with the removal of the negative charges present on Asp30I 
and Glu2I6 in human CYP2D6. The E2I6Q/D30IQ double mutant showed little 
CYP inhibition in the presense of lOO^ uM of quinidine retaining 80% of its bu- 
furalol I-hydroxylase activity and 85% of its dextromethorphan 0-demethylase 
activity. This double mutant was also able to provide quinidine metabolism to 
the 3-hydroxy and 0-demthyl derivatives. Further mutations, E2I6F and FI20A, 
were also able to metabolise quinidine.
Previous modelling work on cytochrome P450 enzymes has been carried out 
by Lewis, see for example [34] and references therein, while Zhang has published 
a machine learning model of species selectivity [35] which has a greater than 80% 
accuracy in predicting selectivity. However, models of this kind do not provide 
information on the three dimensional structure of the active sites of the proteins 
nor the interactions made by the ligands. Using computational techniques, such
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Figure 1.13: The UV difference spectra observed for A quinidine and B quinine 
binding in the human CYP2D6 active site taken from Hutzler et al. [33]. Quini­
dine shows a type I binding spectrum while quinine shows a type II spectrum.
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as homology modelling, molecular docking and surface analysis, new homology 
models of rat CYPs 2D1-2D5 and 2D 18 based on both available human CYP2D6 
crystal structures have been generated (see Chapter 3). Investigations into the 
binding interactions formed and docking positions observed for not only quinidine 
and quinine but also a series of well-known CYP2D6 substrates and inhibitors 
(see Chapters 4 and 5) has been performed and any protein features that may 
affect the species selectivity observed for chiral compounds have been identified 
(see Chapter 6).
1.3 Summary
The aim of this thesis is to identify the cause of the species selectivity in rat 
and human CYP2D enzymes observed for the pseudo enantiomers quinidine and 
quinine. New homology models of rat CYPs 2D1- 2D5 and 2D 18 have been pro­
duced (see Chapter 3) and molecular docking has been performed to investigate 
the amino acid interactions with not only the isomers quinidine and quinine (see 
Chapter 4) but also a series of well known human cytochrome P450 2D6 substrates 
and inhibitors (see Chapter 5). Using this information a simple descriptor has 
been created for the early stage identification of substrates and inhibitors based 
on the orientation of the compound when docked in the active site (see Chapter 
5). Predictions have thus been made as to the more potent isomer of quinidine 
and quinine in rat CYPs 2D5 and 2D 18 for which no experimental binding infor­
mation is currently available and three novel residues have been identified from 
sequence analysis which are proposed to change the more potent diastereomer in 
a series of computational mutation studies (see Chapter 6).
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Chapter 2 
M ethodology
2.1 Introduction
In toxicology and medicinal chemistry, computational methods often provide a 
useful tool for the investigation of protein-ligand interactions. While high resolu­
tion crystal structures of proteins are required for an accurate analysis, computa­
tional methods, such as homology modelling, provide a valuable alternative when 
such structures are unavailable. In this thesis, a combination of computational 
methods has been used to help aid in our understanding of the molecular determi­
nants of reactivity and specificity, potentially contributing significantly to both 
drug development by assisting in the prevention of the growing and expensive 
problem of late stage drug failures (which often occur due to CYP450 mediated 
ADME-Tox properties), and in the reduction (and eventual replacement) of ani­
mal testing at this stage of drug development.
The following tools were used in this project:
P ro te in  D a taB an k  (P D B ) [36], an online database of experimentally- 
determined protein structures used to retrieve the three-dimensional x-ray crystal 
structures used for homology modelling. Various analysis tools and information 
about the entries are available on the website.
P S IP re d  [37], a secondary structure prediction method used in conjunction with
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JPred and Porter for the prediction of rat CYP2D secondary structures.
J P re d  [38], a secondary structure prediction program used in conjunction with 
PSIPred and Porter for the prediction of rat CYP2D secondary structures. 
P o r te r  [39], a secondary structure prediction program used in conjunction with 
PSIPred and JPred for the prediction of rat CYP 2D secondary structures. 
CLU STA LX  [40], a sequence alignment tool used to generate a series of multiple 
sequence alignments comparing rat and human cytochrome P450 2D enzymes. 
M olecu lar O p era tin g  E n v iro n m en t (M C E ) [41], a comprehensive drug dis­
covery software package used for the generation and visualisation of homology 
models, the performance of molecular docking and molecular dynamics studies. 
G aussian  [42], a quantum chemistry tool used for all semi-empirical and molec­
ular orbital calculations performed.
3V W eb Server [43], a collection of online programs for the assessment of vol­
umes in protein files.
2.2 Sequence Analysis
Homology modelling is often based on the assumption that similar protein se­
quences have a similar three dimensional structure. Through the use of detailed 
sequence analysis it is possible not only to generate three dimensional models but 
to investigate amino acid changes beween species which will have an impact on 
the overall performance of the enzyme.
Full length sequences of human and rat cytochrome P450 enzymes were re­
trieved from the Universal Protein Resource (UniProt) [44], a comprehensive 
resource for protein sequence and annotation data, and analysed through the use 
of secondary structure prediction programs and sequence alignment tools.
2.2.1 Secondary Structure Analysis
Secondary structure analysis provides valuable insight into the possible three- 
dimensional structure of an amino acid sequence and can be extremely useful at 
the early stages of homology modelling. It provides a validation for any sequence
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alignments generated and allows for a more accurate consensus match with the 
highest possible sequence identity to be found.
Three programs: PSIPred [37], JPred [38] and Porter [39], were used in com­
bination to predict the secondary structures of the six rat CYP2D enzymes based 
on the protein sequences taken from UniProt [44].
2.2.2 Sequence Alignment
With the number of elucidated protein sequences far exceeding the number of pro­
tein structures, (Figure 2.1), sequence alignment tools provide invaluable insight 
in to the three-dimensional structure of related proteins. However, sequence align­
ment also provides one of the most challenging aspects to the three-dimensional 
modelling of protein structures as any errors at this stage can lead to anomalies 
and inaccuracies in the model formed.
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Figure 2.1: Variation in the number of known protein sequences compared to the 
number of protein crystal structures.
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Using the sequences acquired from UniProt [44], CLUSTALX [40] was used 
to perform a series of multiple sequence alignments (MSA) of all rat and human 
CYP 2D enzymes.
CLUSTALX[40] uses a progressive alignment approach to the multiple se­
quence alignment. This is a heuristic approach with a pre-comparison step used 
to generate a phylogenetic tree for all sequences before the formation of an initial 
pairwise alignment for the two most similar sequences and the subsequent align­
ment of successively less related species. A weighted gap penalty is also employed 
in any situations where a new gap is formed or an existing gap extended during 
the alignment process. As in some cases these sequences show a similarity of 99%, 
this approach can be relied upon to give a reasonably accurate result, however 
in cases where there is less similarity, the retention of the initial pairwise align­
ment can cause the generation of errors and an iterative technique is required [45].
In order to ensure the most accurate alignment possible, MAFFT [46], an 
iterative refinement method was used to confirm the CLUSTALX multialign­
ment. While a similar approach to that of the progressive alignment method­
ology is taken, in this case the initial pairwise sequence alignment is constantly 
re-evaluated during the multiple sequence alignment ensuring that the most ac­
curate alignment possible is achieved.
Comparison of the two alignments produced shows little variation (Figure 2.2) 
with only a two amino acid difference being observed at the gap opening of the 
human CYP2D6 N-terminus.
2.3 Homology M odelling
Homology modelling allows for the creation of a three-dimensional model based 
on available protein sequences for which no experimental structural information 
is available.
The Molecular Operating Environment (MCE) [41] was used to generate
25
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C l u s t a l X  A l i g n m e n t
RAT CYP2D1 KELLNGTGLWSKAIFTVIFILLVDLKHRRHRWTSRYPPGPVPWPVLGNLLQTOLSNKPYS
RAT CYP2D2 MGLLIGDDLWAWIFTAIFLLLVDLVHRHKFWTAHYPPGPVPLPGLGNLLQVDFENMPYS
RAT CYP2D3 MELLAGTGLWPKAIFT\^IFILL\T3LKHRRQRWTSRYPPGPVPWP'î7LGNLLQVDLCNMPYS
RAT CYP2D4 KRMPTGSELWPIAIFTIIFLLLVDLKHRRQRWTSRYPPGPVPWPVLGNLLQIDFQNMPA-G
RAT CYP2D5 MELLNGTGLWPKAIFT\riFILLVDLKHRHQRWTSRYPPGPVPWPVLGNLLQVDPSNKPYS
HUMAN CYP2D6 MGLEA L\T>LAVIVA.IFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYC
RAT CYP2D18  MRMPTGSELWPlAI F T I IFLLLVDLMHRRQRWTSRYPPGPVPWPVLGNLLQIDFQNMPAG 
* • * - • •  * *  - * * * * * *  - * *
MAFFT A l i g n m e n t
RAT CYP2D1 MELLNGTGLWSMA-IFTVIFILLTOLMHRRHRWTSRYPPGPVPWPtULGNLLQVDLSNMPYS
RAT CYP2D2 MGLLIGDDLWAWIFTAIFLLLVDLVHRHKFWTAJiYPPGPVPLPGLGNLLQVDFENMPYS
RAT CYP2D3 MELLAGTGLWPMA-IFTVIFILLVDLMHRRQRWTSRYPPGPVPWPVIGNLLQVDLCNMPYS
RAT CYP2D4 MRMPTGSELWPlAIFTIIFLLLVDLD'aiRRQRWTSRYPPGPVPWPVLGNLLQIDFONMPAG
RAT CY P2D 5  MELLNGTGLWPMAI FT*y I F ILL  VDLMHRHQRWT SRYPP GPVPW PVL GNLLQTOP SNMPY S
HUMAN CYP2D6 MGL EALVPLAVIVAIFLLLTOLMHPAQRWAARYPPGPLPLPGLGNLLHTOFQNTPYC
RAT C Y P2D 18 MPMPTGSELWPIAIFTIIFLLL'^/DLMHRRQRWTSRYPPGPVPWPVLGNLLQIDFQNMPA.G 
* « * • • •  * * « * * * * * « * * "  - I Z - * * * * * * * *  * *
Figure 2.2: A comparison of the CLUSTALX and MAFFT protein sequence 
alignments for the first 60 residues.
twenty-five three-dimensional homology models for rat cytochrome P45Ü 2D1- 
2D5 and 2D 18. The models were based on the available human CYP2D6 crystal 
structures both with a ligand bound in the active site (PDB entry code 3QM4 
[9]) and without (PDB entry code 2F9Q [8]), using the sequence alignment from 
CLUSTALX. The MCE automatic alignment program has four basic steps:
1. An initial partial geometry for the target sequence is first taken from the 
template crystal structure with heavy-atom coordinates of any conserved 
residues being retained.
2. Any residues with no allocated backbone coordinates are then defined as; 
loops (an insertion in the model with respect to the template), outgaps (a 
residue aligned before the C-terminus or after the N-terminus of the tem­
plate) or deletions (a deletion in the model with respect to the template). 
In the case of deletions, the copied template geometry is unlikely to be cor­
rect and so is ignored, instead they are modelled using protein fragments 
taken from the Protein Data Bank (PDB) [36, 47] which are superimposed
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onto the anchor residues on either side of the insertion [48, 49].
3. When all the residues have assigned coordinates, a collection of intermedi­
ate models can be created. Loops are modelled first using a contact energy 
function to assess possible template structures found in the PDB before 
using the energies to make a Boltzmann-weighted choice of template. Side 
chains are modelled using data taken from a rotamer library generated from 
the clustering of PDB data. The optimal packing is selected using an opti­
mization based approach before hydrogen atoms are added to complete the 
valence requirements. The models are then minimized under a force field 
to remove any steric strain before being written to an output database [50].
4. The final model is selected based on the best-scoring intermediate model 
[51-54].
The models were generated under both the AMBER99 and CHARMM27 force 
fields.
2.4 Force Fields
Owing to the large size of protein systems, it is not always possible to use ab initio 
or semi-empirical methods to calculate the potential energy surface as the com­
putational power and time required far outweighs the usefulness of the provided 
results. Energy minimisation of protein systems is therefore most commonly per­
formed using molecular mechanics force fields which provide an empirical solution 
for the potential energy surface. These force fields use a collection of geometric 
terms such as bond angle, length and the associated force constants which are 
derived experimentally with supplementary information derived from first prin­
ciples, using molecular orbital theory.
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Molecular mechanics forcefields can also be used in conjunction with ab initio 
methods. Molecular mechanics is used to model the overall protein system while 
ab initio methods are used to more accurately model the principal area of inter­
est, known as quantum mechanics\molecular mechanics (QM\MM).
2.4.1 AM BER99
AMBER99 [55] is one of the most popular all-atom force fields currently available. 
It has been parameterised specifically for proteins, nucleic acids and a number of 
related organic molecules.
The functional form of the AMBER force field is:
^total — ^bond T ^angle “b ^torsion T  ^non—bonded (^4)
Simple harmonic functions are used to describe the first two terms of the force 
field, Ei)QYid and E^ jigiQ.
The first term, E^ond, describes the bond energies;
Ebond = kb{l — /q)  ^ (2.2)
b
where kb is the force constant, I is the bond length and Iq is the ideal bond 
length.
The second term, Eangles describes angle strain;
Eangle = ~  Oof (2.3)
e
where kg is the force constant, 0 is the bond angle and Oq is the ideal bond 
angle.
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The third term, Etorsion, is used to describe the torsion energy and is expressed 
as a fourier series as a single bond may contribute more than one of these terms;
E to r s io n  = +  COs{n(f) — 0o)] (2-4)
where 14 is the barrier to rotation, n  is the periodicity, (j) is the torsion angle 
and (j)o is the phase factor.
The fourth term, Enon-bonded, describes the non-bonded energies between all 
atom pairs i.e. all van der Waals and electrostatic interactions.
Enon—bonded — E^^yj T E Qi^dj-ostatic (2-5)
Van der Waals forces, Eydw  ^ the interaction energy of permanent and induced 
dipoles can be modelled using the Lennard-Jones potential.
(2.6)
where r is the non-bonded distance, is the minimum energy distance and 
£ is the depth of the potential well.
The term describes the Pauli repulsion due to overlapping electron orbitals 
and the r® term describes long range attraction.
The electrostatic interactions, Eelectrostatic, can be modelled using Coulomb’s 
law;
EelectrosUUic = y 2 —  (2.7)^ijEj
where q is the atomic charge, e is the dielectric constant and r is the non- 
bonded distance.
In MOE, a number of modifications have been implemented in the AMBER99
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force field, including a restrained electrostatic potential, an extra term to describe 
the polarization potential [56] ; and an effective charge model designed to emulate 
the ah initio electrostatic potential [57].
2.4.2 CHARM M 27
CHARMM27 [58], like AMBER99 [55], is an all-atom force field parameterised 
for proteins, DNA, RNA and lipids.
The functional form of the CHARMM force field is:
E to ta l  — E i)ond~^ E a n g le E  E d ih e d ra ls~ ^  E im p ro p erd ih ed ra l~ ^  E j j r e y —B ra d ley  E n o n —bonded
(2.8)
Once again the first two terms, E^ond and Eangle, are represented by simple 
harmonic functions. Equations 2.2 and 2.3 respectively.
The third term, E d ih e d ra i,  is a measure of the dihedral or torsion angles and 
again uses the same periodic Fourier description as used in the AMBER force 
field. Equation 2.4.
The fourth term, E im p ro p erd ih ed ra l, is a measure of the out of plane torsion 
angles;
E im p ro p erd ih ed ra l ^  ^ a^o) ( 2 -9 )
w
where ka, is the force constant, w is the out of plane bond angle and ujq is the 
ideal bond angle.
The fifth term, Eurey-Sradiey, IS a cross term which accounts for angle bending 
using 1, 3 non-bonded interactions;
E j j r e y —B ra d ley  ^   ^ky(u Ug) (2.10)
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where ky is the force constant, u is the 1, 3 non-bonded distance and Uq is the 
ideal bond distance.
The sixth term, Enon-bonded, as in AMBER describes the non-bonded ener­
gies between all atom pairs i.e. all van der Waals and electrostatic interactions 
(Equations 2.6 and 2.7).
Once again, MOE makes a few alterations to this force field including a partial 
charge dictionary [58, 59].
2.5 Site Identification
The active site was defined using available site-directed mutagenesis data (SDM) 
and rigid docking data taken from literature (Table 2.1) [1].
Residue Number CYP2D1 CYP2D2 GYP2D3 GYP2D4 CYP2D5 GYP2D6 GYP2D18
106 He He He Phe He He Phe
110 Leu Leu He Ser Leu Leu Ser
112 Val Tyr Tyr Phe Val Phe Phe
117 Gin Lys Lys Gin Gin Gin GLn
118 Gly Gly Gly Gly Gly Gly Gly
119 Val Val Val Val Val Val Val
120 He Val Val Val Val Phe Val
121 Leu Leu Leu Leu Phe Leu Leu
122 Ala Ala Ala Ala Ala Ala Ala
213 Leu Phe Met Leu Leu Leu Leu
216 Val Asp Gin Glu Val Glu Glu
220 He Met Phe Leu He Leu Leu
244 Gin Leu Gin Lys Gin Gin Lys
247 Phe Phe Phe Phe Phe Phe Phe
248 Met He Leu Val Met Leu Val
297 Met Leu Leu Val Met He Val
300 Val He Asn Ala Val Ala Ala
301 Asp Asp Asp Asp Asp Asp Asp
304 Thr Met Gly Met Thr Ser Met
307 Met Met Met Met Met Met Met
308 Val Val Val Val Val Val Val
309 Thr Thr Thr Thr Thr Thr Thr
370 Ala Val Val Leu Ala Val Leu
373 Asn Asn Asn Gly Asn Gly Gly
374 Leu He Leu Val Leu Met Val
483 Phe Leu Phe Ala He Phe Ala
484 Pro Pro Leu Leu Ser Leu Leu
Table 2.1: Residues in the literature defined active site.
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2.6 Docking
A number of known inhibitors, including quinidine and quinine, and substrates of 
human cytochrome P450 2D6 (Figure 2.3) were docked into both the compound 
1 and the haem structures of human CYP2D6 [8, 9] and rat CYP2D homology 
models using the available MOE [41] docking program. In previous work from 
our group [60] results more consistent with experimental work have been achieved 
by docking the x-ray crystal structure of the ligand rather than a model built up 
on an atom by atom basis. Therefore we have also docked the available x-ray 
crystal structure of quinidine.
The MOE docking program follows a series of five steps to produce 25 possible 
ligand poses for each compound docked;
1. A brief conformational analysis of each ligand is performed by investigating 
any available rotatable bonds.
2. The Alpha Triangle placement method is used to generate possible ligand 
poses through the superposition of randomly selected ligand atom triplets 
and receptor site triplets.
3. An initial scoring step is performed, using the London AG scoring function, 
to estimate the free energy of binding for each ligand pose;
A G  =  C-]- Ef iex +  ^  C H B f n B +  ^  ^  A D i  (2.11)
h—bonds m —lig  a tom si
where c is the average gain/loss of rotational and translational entropy, 
Efiex is the energy due to increasing bond rigidity, / hb is the geometric 
imperfections of the hydrogen bonds, chb is the energy of an ideal hydro­
gen bond, /m is the geometric imperfections of metal ligations and cm is
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the energy of ideal metal ligation and Di is the desolvation energy of atom i.
4. A GridMin refinement step is employed to carry out an energy minimization 
of the system. While forcefield based refinement is usually considered more 
accurate, in this case it caused some anomalies to occur in the aromatic 
rings of the docked compounds.
5. A second and final scoring step is then performed again using the London 
AG scoring function.
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2.6.1 GridMin
GridMin provides a quick energy minimisation step by using a grid for the calcula­
tions performed during the minimisation process. A distance-dependent dielectric 
model is employed with explicitly treated van der Waals interactions using the 
softer 4-8 potential to reduce the penalty for atom clashes.
=  2 ( ^ ) 1  (2.12)
where r is the non-bonded distance, is the minimum energy distance and 
s is the depth of the potential well.
The final electrostatic energy is then calculated using the explicit Coloumb 
potential. A penalty will be applied if any of the energy minimised poses lie 
within 2Â of a receptor residue or outside of the defined active site [61, Docking].
2.7 Molecular Dynamics
A series of molecular dynamics (MD) simulations were performed using MOE 
[41] in vacuo to judge the stability and quality of the homology models gener­
ated. The simulations were performed using the Isobaric-Isothermal ensemble 
(NPT), which holds the number of atoms, the pressure and the temperature con­
stant throughout the simulation while allowing volume to vary. This ensemble 
was chosen as the simulations were performed at body temperature and pressure 
which is not normally subject to change in biological systems.
Molecular dynamics simulations are based on Newton’s second law of motion:
F  = ma  (2.13)
where F  is the force acting on an atom, m  is its mass and a its acceleration.
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This can also be expressed as:
^  ^ dv d?r
F  = ma = m —  = m-r^r (2.14)
dt dF
As acceleration is a derivative of velocity with respect to time:
- S  (2.15)
we can obtain an expression for velocity:
(2.16)
v = j  ddv 
V = at + Vo 
where Vq is the initial velocity.
And as velocity is a derivative of position with respect to time:
the position can be determined by: 
r =  vdt
V (2.18)
r = vt-\-ro 
where Vq is the initial position.
These equations can then be combined to give the position of an atom, r, at 
a time, t, as a function of acceleration, a, initial position, ro, and initial velocity.
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V q .
X = d t ^ V qI V q (2.19)
Therefore in order to calculate a trajectory that will describe the position, 
velocity and acceleration of the atoms as they vary with time, only the initial po­
sition of the atoms, initial distribution of velocities and acceleration is required.
The initial atom positions are taken from the experimental crystal structures 
or homology models, while the inital distributions of velocities and acceleration 
must first be calculated. The initial velocities are usually determined from a 
random distribution with the magnitudes conforming to the required temperature 
and corrected to ensure no overall momentum:
N
p  =  =  TUiVi =  0 (2.20)
i^l
where Vi is the velocity, often chosen at random from a Maxwell-Boltzmann 
or Gaussian distribution at a given temperature. This gives the probability that 
an atom, i, has a velocity, in the x  direction at a temperature, T.
The temperature, T, can then be calculated using:
1 = 1
where N  is the number of atoms in the system.
The acceleration can be determined by the gradient of the potential energy
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function. Force can be expressed as a gradient of potential energy:
Fi = - V E  =  (2,23)
dr
where E is the potential energy of the system.
Acceleration can then be defined as a derivative of the potential energy with 
respect to a position:
As the potential energy is a function of the atomic position, 3A, of all atoms 
in the system this problem is too complex to solve analytically and so must be 
solved numerically instead. In this case a Leap-frog algorithm is used.
This algorithm first assumes that all the positions, velocities and accelerations 
can be approximated by a Taylor series expansion:
r{t 4- St) =  r{t) H- v{t)S{t) +  ^a(t)St ‘^ -|- ...
v{t -t- St) = v{t) +  d{t)S{t) 4- ^b{t)St‘^ + ... (2.25)
Ci(t +  St) = Oj{t) -|- b(t)S(t) 4" —c(t)(^t^ H- ...
The velocities are calculated first at time t  = ^St:
v{t F  ^St) + v{t — ^St) + d{t)St (2.26)
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then the positions are calculated at time t-\- ôt:
r{t +  ôt) = r{t) +  v{t +  ^ôt)ôt (2.27)
The velocities therefore, must first leap over the positions before the position 
leaps over the velocities, hence the name.
The equations of motion method used by molecular dynamics simulations is 
deterministic thus allowing us to predict the state of the system at any time when 
the initial position and velocities are known [62].
2.7.1 Low M ode MD
Protein fiexibility was investigated using a series of low mode MD conformational 
searches. This method employs a relatively simple technique of alternating en­
ergy minimisation and molecular dynamics simulations along low mode vibrations 
assigned by a stochastic velocity generation step [63]. It is computationally very 
efficient making it useful in the conformational search of large systems.
2.8 Density Functional Theory
Density functional theory (DPT) provides a useful tool for the investigation of the 
electronic structure and ground-state of a many atom system. Unlike the more 
traditional ah initio methodologies such as the Hartree-Fock method, DPT makes 
no attempt to approximately solve the many electron Schrodinger equation but 
instead approximates the local electron density before solving the much simpler 
single electron problem [64].
A computational scheme using the Kohn-Sham equations is generally used;
E k s  = V + < h P > + ^ <  PJ(P)  > +E^[P] +  E,[P\ (2.28)
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where V  is the nuclear repulsion energy, P  is the density matrix, < hP > 
is the one-electron (kinetic and potential) energy, |  < PJ{P)  > is the classical 
coloumb repulsion of electrons, Ex[P] is the exchange functional and Ec[P] is 
the correlation functional. The functionals used are integrals of some function of 
density and possibly the density gradient.
Ex[P] = J  fiPa{r),pp{r), Vpa{r), Vp^{r))dr (2.29)
where methods differ in which function, / ,  is used for E^ and which, if any, 
is used for Exc­
using Gaussian [42], the ground states of both the haem and the compound 
1 structures were investigated. In this case a hybrid functional, B3LYP [65], was 
used where the exchange functional is a linear combination of the Hartree-Fock 
exchange and the DFT exchange-correlation, and a 6-31G* basis set [64].
2.9 Surfaces and Maps
A surface analysis of the active sites of both the rat and human GYP2D struc­
tures was performed using the surface mapping tool available within MOE [41].
A Gonnolly surface, [66, 67] also known as a solvent excluded surface was 
formed of the sovent inaccessible volume of the active site before applying an 
electrostatic map. The electrostatic map was formed using a Poisson-Boltzmann 
equation (Equation 2.33) to predict the electrostatically preferred locations of the 
hydrophobic, H-bond donor and H-bond acceptor regions.
The Poisson-Boltzmann equation is derived from the Poisson Equation;
V^u(r) -P [fi{r) 4- / ( r ) ]— =  0 (2.30)
6o
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where u is the electrostatic potential, /  is the charge density, / /  is the mobile 
ion charge density, e is the electron charge, eo is the absolute permittivity and 
is the Laplacian operator in the form;
and the Boltzmann Equation;
where Q is the Boltzmann distribution, q is the charge and i/j is the spacial 
potential.
For large |r| both u and i/j disappear and ^  is taken to be the bulk number 
concentration, C, of the mobile charge.
The Poisson-Boltzmann equation therefore takes the form;
V^u(r) 4- { q C e x p [ - / ( r ) ) ^  =  0 (2.33)
This equation is then used to form iso-contour maps for each region, with 
the acceptor region taking the form of the potential qo{u) 4- i^o where qo is the 
partial charge of the oxygen ion and i/q is the van der Waals potential, the donor 
region taking the form of qnu 4- ph where H represents polar hydrogen and the 
hydrophobic regions takes the form —{qo +  (Ih )u 4- pc where Pc is the van der 
Waals potential of a carbon atom [61, Surfaces and Maps].
OPLS (Optimised Potentials for Liquid Simulations) [68] van der Waals pa­
rameters are used for the receptor and mobile ions.
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2.10 Volume Calculation
The volume of the active site surface was calculated using the 3V web server [43]. 
This server uses the rolling probe method [69-71] which essentially rolls a virtual 
probe of a given radius (in this case 3Â) around the van der Waals surface of the 
molecule to find the solvent-excluded surface area and volume.
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Chapter 3 
Hom ology M odelling of Rat 
Cytochrom e P450 2D Enzymes
3.1 Introduction
Given the importance of rats to toxicological safety testing in the pharmaceu­
tical industry, homology models of the rat cytochrome P450 2D enzymes have 
been generated within MOE [41] based on a multiple sequence alignment from 
GLUSTALX [40]. Modelling haem containing enzymes with conventional molec­
ular mechanics methods can however be problematic due to the transition metal 
centre. Transition metals provide a number of challenges to molecular mechan­
ics that are not normally observed in organic systems such as high coordination 
numbers, variable oxidation states, variable spin states and electronic effects such 
as Jahn-Teller distortions [72]. A comparison has been performed of the effec­
tiveness of two of the most common all-atom force fields parameterized for large 
biomolecules, AMBER99 [55] and GHARMM27 [58], in accurately modelling the 
haem group.
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3.2 Homology M odelling of Rat CYP2D1
3.2.1 M odels Generated Under the AM BER99 Force Field
Using the multiple sequence alignment generated using GLUSTALX (Figure 3.1), 
which shows a high sequence identity of %57% between all rat GYP2D enzymes 
and %56% between rat and human GYP2D enzymes, up to 25 three-dimensional 
homology models of rat cytochrome P450 2D1 were generated under the AM- 
BER99 force field based on both the available human GYP2D6 crystal structures 
(2F9Q [8] and 3QM4 [9]).
The homology models were analysed using Ramachandran plots to identify 
residues with unusual conformations and the root mean square of deviation 
(RMSD) of the a-carbons from the crystal structure. Overall models generated 
using the AMBER99 force field showed an average deviation of 0.61Â and an 
average of 1.5% of residues showing conformations in disallowed regions of the 
Ramachandran plot (% 7 outliers) when based on the 2F9Q crystal structure 
[8]. This deteriorates slightly in results for models based on the 3QM4 crystal 
structure [9] showing an average deviation of 0.67Â and 1.5% of residues with 
disallowed conformations (~  7 outliers). The models with the lowest value for 
the RMSD, the best Ramachandran plot and no apparent visual protein structure 
defects were then chosen for further analysis and docking.
For models based on 2F9Q, model number 19 of 25 was identified as the best 
model for continued research showing an RMSD of 0.66Â with 0.9% of residues 
(% 4 outlying residues) showing conformations in disallowed regions (Figure 3.2). 
Further investigation into these outlying amino acid residues showed them to be 
on the protein surface, and outside of the active site (Figure 3.3).
Fewer models were generated for the 3QM4 crystal structure of which model 
1 was identified as the best model showing an RMSD of 0.53Â with 0.9% of 
residues (% 4 outliers) again showing disallowed conformations (Figure 3.4). In 
this case further investigation into these amino acid residues showed tha t while
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Figure 3.1: Multiple sequence alignment of all Rat and Human CYP2D Enzymes. 
The predicted positions of the a-helices are shown in red, ^-sheets in yellow and 
fyturns in blue and the locations of the substrate recognition sites labelled.
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Figure 3.2: Ramachandran plot showing the favorability of the dihedral and 
0  angles of the backbone amino acid residues in the AMBER99 model of rat 
CYP2D1 based on the 2F9Q crystal structure of human CYP2D6. The green 
and orange lines represent the favoured and allowed regions with the green points 
representing amino acid residues with favoured dihedral conformations, yellow 
showing those with allowed conformations and red those amino acids with disal­
lowed conformations.
A  Val470 \ y
Figure 3.3: Location of the outlying amino acid residues in the 2F9Q based
AMBER99 model of rat CYP2D1 taken from the Ramachandran plot. Ser 148 is
shown in green, Lys283 in pink, Asp386 in orange and Val470 in blue.
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the majority of residues were again found on the protein surface (Figure 3.5), one 
residue, Ser437, was found to hydrogen bond to a car boxy lie acid of the haem 
group well within the active site (Figure 3.6). This outlier was found for all AM- 
BER99 3QM4 based models of CYP2D1.
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Figure 3.4: Ramachandran plot showing the favorability of the dihedral T and 
0  angles of the backbone amino acid residues in the AMBER99 model of rat 
CYP2D1 based on the 3QM4 crystal structure of human CYP2D6. The green 
and orange lines represent the favoured and allowed regions with the green points 
representing amino acid residues with favoured dihedral conformations, yellow 
showing those with allowed conformations and red those amino acids with disal­
lowed conformations.
3.2.2 M odels Generated Under the CHARM M 27 Force 
Field
Again using the multiple sequence alignment generated using GLUSTALX (Fig­
ure 3.1), homology models of rat cytochrome P450 2D1 were generated under 
the CHARMM27 force held based on both the 2F9Q [8] and 3QM4 [9] human 
CYP2D6 crystal structures. The models formed were analysed both visually and
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i a
Figure 3.5: Location of the outlying amino acid residues in the 3QM4 based 
AMBER99 model of rat CYP2D1 taken from the Ramachandran plot. Alal92 is 
shown in green, Lys283 in pink, Phe387 in orange and Ser437 in blue.
Figure 3.6: Outlier Serine 437, shown in blue, hydrogen bonds with a carboxylic 
acid group of the haem as indicated by a blue line.
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statistically within MOE [41] and molecular dynamics studies performed in vacuo 
to confirm model stability.
Models generated based on the CHARMM27 force field [58] showed an over­
all improvement in results when compared to those models generated using the 
AMBER99 force field [55], with an average deviation of o-carbons of 0.57Â and 
an average of 0.9% of residues showing conformations in disallowed regions of the 
Ramachandran plot (% 4 outliers) for models based on the 2F9Q crystal struc­
ture [8]. For models based on 3QM4 [9] the RMSD from the crystal structure 
increased to 0.59Â and again an average 0.9% of residues were found with disal­
lowed conformations (~  4 outliers).
For models based on 2F9Q, model number 7 of 25 was identified as the best 
model for continued research showing an RMSD of 0.55Â and an average 0.9% of 
residues in disallowed conformations (~  4 outliers) (Figure 3.7). Further investi­
gation into these outlying amino acid residues showed them to be on the protein 
surface, and therefore outside of the active site (Figure 3.8).
For the 3QM4 crystal structure of which model 14 of 25 was identified as the 
best model showing an RMSD of 0.54Â and an average 0.9% of residues (% 4 
outlying residues) showing disallowed conformations (Figure 3.9). Again further 
investigation into these amino acid residues showed them to be on the protein 
surface, and therefore outside of the active site (Figure 3.10). In this case Ser437 
was found in the allowed region of the Ramachandran plot.
3.3 M odelling Transition M etals with M olecu­
lar Mechanics
Molecular Mechanics force fields provide a quick and computationally inexpensive 
method for modelling large and complex chemical systems making them ideal for 
use in protein modelling. By treating atoms as simple classical springs, it is pos-
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Figure 3.7: Ramachandran plot showing the favorability of the dihedral ^  and 
0  angles of the backbone amino acid residues in the CHARMM27 model of rat 
CYP2D1 based on the 2F9Q crystal structure of human CYP2D6. The green 
and orange lines represent the favoured and allowed regions with the green points 
representing amino acid residues with favoured dihedral conformations, yellow 
showing those with allowed conformations and red those amino acids with disal­
lowed conformations.
C ■#.
Figure 3.8: Location of the outlying amino acid residues in the 2F9Q based
CHARMM27 model of rat CYP2D1 taken from the Ramachandran plot. Met 144
is shown in green, AlalGS in pink, Ala229 in orange and Ser288 in blue.
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Figure 3.9; Ramachandran plot showing the favorability of the dihedral ^  and 
d> angles of the backbone amino acid residues in the CHARMM27 model of rat 
CYP2D1 based on the 3QM4 crystal structure of human CYP2D6. The green 
and orange lines represent the favoured and allowed regions with the green points 
representing amino acid residues with favoured dihedral conformations, yellow 
showing those with allowed conformations and red those amino acids with disal­
lowed conformations.
a
Figure 3.10: Location of the outlying amino acid residues in the 3QM4 based
CHARMM27 model of rat CYP2D1 taken from the Ramachandran plot. Val42
is shown in green, Asp67 in pink, Lysl47 in orange and Alal92 in blue.
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sible to model their behaviour without having to explicitly model the electrons, 
thus reducing the required computational power. Due to the large number of 
parameters required to model molecular systems, force fields are usually associ­
ated with a specific class of compounds. CHARMM and AMBER are two of the 
most popular force fields parameterised for large biomolecules. For the majority 
of protein systems this is all that is required, however in this case the transition 
metal iron in the prosthetic haem group presents a problem. The possibility of 
high coorodination numbers, variable oxidation states, variable spin states and 
electronic effects in transition metals leads to a varied geometry which cannot be 
accounted for by conventional molecular mechanics force fields.
For simple small organic molecules, sp, sp^ and sp^ hybridisation states for 
carbon atoms are associated with a single reference bond angle - angles 180°, 120° 
and 109.5° which are the bond angles for linear, trigonal planar and tetrahedral 
structures respectively (Figure 3.11).
180.0 ® ®
109
Figure 3.11: The single reference bond angles for carbon hybridisation states.
In contrast, transition metal centres exist in coordination geometries that 
require multiple reference angles, known as the “unique labelling problem” as 
termed by Landis et al. [73] (Figure 3.12).
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180
120,
90.0
80.0
90.0
.0
Figure 3.12: The multiple reference bond angles possible for transition metal 
centres.
3.3.1 M odelling the Haem in Cytochrome P450 2D En­
zymes with Molecular Mechanics
While both RMSD and Ramachandran analysis suggests that models produced 
using the CHARMM27 force field provide a model structure closer to that of the 
available CYP2D6 crystal structures than those formed by AMBER99, it is im­
portant to consider how the haem group has been modelled given its importance 
to enzyme metabolism (see Chapter 1, Figure 1.10).
The transition metal iron of the haem group coordinates to the four nitrogen 
atoms of the porphyrin, the sulfur atom of Cys443 and has a sixth coordination 
site that is open to the binding of small extraneous ligands. In the resting state, 
the sixth coordination site is occupied by a water molecule and the iron is in a 
low spin Fe(III) state. Given the difficulties associated with modelling transition 
metals using conventional molecular mechanics techniques, a comparative anal­
ysis of these force fields has been performed for haem structures produced both 
during the homology modelling step and for energy minimised molecular struc­
tures. An idealised structure has also been produced for comparison using DFT 
[64], however, due to the large size of the haem group and the associated com­
putational expense, only the core Iron-porphyrin group was included in the model.
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During the homology modelling step, haem structures were generated based 
on the observed haem group within the crystal structures. In the 2F9Q crystal 
structure [8] the haem group appears to be pentacoordinated with Cys443 with 
no ligand or water molecule bound in the sixth coordination site (Figure 3.13).
Figure 3.13: The prosthetic haem group of the 2F9Q crystal structure of human 
CYP2D6 [8].
The 3QM4 crystal structure [9] shows the iron to be hexacoordinated with 
the substrate prinomastat in the sixth coordination site (Figure 3.14).
For models based on 2F9Q, root mean squared deviations for all haem atoms 
from the crystal structure of 0.47Â and 0.73Â were found for the CHARMM27 
and AMBER99 force fields respectively, while for models based on the 3QM4 
crystal structure, the RMSD is decreased to 0.46Â for models generated under 
the CHARMM27 force field and 0.53Â for those generated under AMBER99. The 
major difference in structure appears to be the movement of the haem iron out-of- 
plane with the tetrapyrroles seen in all homology models (see for example Figure 
3.15). By measuring the distance between the crystal structure iron (Fe(Ct)) and 
the model iron (Fe(MM)) this nonplanar distortion can be quantified (Table 3.1).
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CHARMM27 Force Field
Atom Rat CYP2D1 (2F9Q) Rat CYP2D1 (3QM4)
Distance /  A Distance /  A
Fe(Ct)-Fe(MM) 0.31 (133
AMBER99 Force Field
Atom Rat CYP2D1 (2F9Q) Rat CYP2D1 (3QM4)
Distance /  A Distance /  A
Fe(Ct)-Fe(MM) 0.30 0.45
Table 3.1: Nonplanar distortions of the homology modelled haem iron (Fe(MM)) 
and the crystal structure haem iron (Fe(Ct)).
As you can see this distortion measures around 0.30Â for models generated based 
on the 2F9Q crystal structure with more variation being observed for the 3QM4 
based models.
This nonplanar distortion of the haem iron must have a direct effect on its 
octahedral geometry. Valence shell electron pair repulsion (VSEPR) theory sug­
gests that an octahedral structure will have ideal bond angles of 90° and 180°; 
however, analysis of the bond angles of the crystal and homology model haems 
shows that this is not the case with the majority of the variation occuring at the 
axial ligands (Table 3.2). Overall, the models based on the 2F9Q crystal structure 
show an average percentage deviation of 3.7% from the ideal while those based 
on 3QM4 show a smaller average deviation of 2.2%.
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Figure 3.14: The hexacoordinate prosthetic haem group of the 3QM4 crystal 
structure of human CYP2D6 [9].
Figure 3.15: An overlay of the haem structure of the human CYP2D6 2F9Q 
crystal structure (green) showing the out-of-plane iron observed in the homol­
ogy model haem structure of rat CYP2D1 (pink) when generated under the 
CHARMM27 force field.
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Atom Crystal Structure
2F9Q Crystal Structure 
CHARMM27 Model AMBER99 Model
Distance /  A Distance /  A Distance /  A
M-Npor 2.000 2.042 2.043
3QM4 Crystal Structure
Atom Crystal Structure CHARMM27 Model AMBER99 Model
Distance /  A Distance /  A Distance /  A
M-Npor 2.050 2.035 1.957
Table 3.3: Metal to porphyrin nitrogen bond length in Â.
While the majority of the variation occurs at the axial ligands, the crystal 
structures appear to show more deviation from the ideal in the porphyrin bond 
angles than those structures generated using molecular mechanics force fields. De­
spite conjugation of the tt systems in the tetrapyrroles, porphoryinoid complexes 
are suprisingly flexible and can undergo a number of nonplanar conformational 
changes (Figure 3.16) [74].
Analysis of the porphyrin in the 2F9Q based crystal structure shows a slightly 
domed structure while the 3QM4 crystal structure haem has a slight wave. For 
the homology model haem structures, the porphyrins show a slight wave for those 
based on the 2F9Q crystal structure while those based on the 3QM4 structure 
show a saddle conformation for models generated under the CHARMM27 force 
field and a ruffled conformation for models generated under AMBER99. Given 
the out-of-plane nature of the model haem iron, this analysis was performed based 
on the tetraazaplane [74, 75].
In the past, this out-of-plane iron distortion had been suggested to be due to 
the large high spin Fe(II) [75], however, research has shown the porphyrin core to 
be very flexible suggesting that this extrusion is due to electrostatic rather than 
steric reasons. In fact an ideal M-Nporphyrin bond length of 2.04Â has been deter­
mined. Overall the structures show an M-Nporphyrin bond length relatively close 
to the ideal with the model structures showing a close correlation between the 
out-of-plane iron distortion and the M-Nporphyrin bond length (Tables 3.1 and 3.3).
During the course of this thesis, docking will be performed not only with the
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0
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PropellerWave (y)
Figure 3.16: Common distortion modes of metalloporphyrins [74].
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inhibitors quinidine and quinine but also with known CYP2D6 substrates and, 
as such, it is important to also consider how these molecular mechanics force 
fields model the reactive transition state, compound 1 (see Chapter 1, Figure 
1.10) [23]. In this case, for modified models based on the 2F9Q crystal struc­
ture, RMSD values from the crystal structure of 0.40Â and 1.23Â were found 
for CHARMM27 [58] and AMBER99 [55] respectively, while for models based 
on 3QM4 show RMSD values of 0.75Â and 1.03Â. Again the major difference 
in structure appears to be the movement of the haem iron out-of-plane with the 
tetrapyrroles (Figure 3.17). In fact for compound I this out-of-plane distortion 
dramatically increases (Table 3.4).
Figure 3.17; An overlay of the compound 1 form of the human CYP2D6 2F9Q 
crystal structure (green) showing the out-of-plane iron observed for the compound 
1 form of the homology model structure of rat CYP2D1 (pink) when generated 
under the CHARMM27 force field.
Again, this nonplanar haem iron distortion has an effect on the octahedral 
geometry with the majority of the variation occuring at the axial ligands (Table 
3.5). Overall the models based on the 2F9Q crystal structure show an average 
percentage deviation of 5% from the ideal while those based on 3QM4 show a
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CHARMM27 Force Field
Atom Rat CYP2D1 (2F9Q) Rat CYP2D1 (3QM4)
Distance /  A Distance /  A
Fe(Ct)-Fe(MM) 0.76 (169
AMBER99 Force Field
Atom Rat CYP2D1 (2F9Q) Rat CYP2D1 (3QM4)
Distance /  A Distance /  A
Fe(Ct)-Fe(MM) 0.78 0.70
Table 3.4: Nonplanar distortions of the homology model iron (Fe(MM)) and the 
crystal structure haem iron (Fe(Ct)) in compound 1.
smaller average deviation of 4.7%.
In general, conventional molecular mechanics force fields are not recommended 
for structures containing transition metals due to the so called “unique labelling 
problem” where coordination geometries are encountered that require multiple 
reference bond angles, (Figure 3.12) rather than the single reference bond an­
gle required for the molecular geometries encountered in simple organic small 
molecules (Figure 3.11). While this multiple reference problem can be solved 
through the use of a number of specialised force fields, such as LFMM [76], which 
incorporates the ligand field stabilisation energy into the potential energy expres­
sion and SHAPES [73] which uses a Fourier transform to describe the angular 
potential, in this case it was deemed unnecessary.
62
3. Homology Modelling of Rat CYP2D Enzymes
i
CO
3
I
1
Î
1
CQ
O’Gn
5
8
B
I
i
CO
3
k
(D
I
b -04
I
8
B
I
t
I
O’
O i
5
8
B
I
ao
<
t
opq
1—I'^COOiCOi—l'^COi—ICOOCO
O i 03  00 00 0300C-03001>UOi—I03CM 00 00 00t^l>-000300303
!>- b-
00 03 00 00
OC0>t>-00T-H03L003t^i:0 
03 03 c5'^*COi-H03Ldc0l>P 00 00 03 0 0 I>-0003030303
CO
o6 03 00 00
;l>;oqooO03i-Î03l>:C0CÔl>^i—îio 03 00 03 001>-t^0030303
CM ^
00 GÔ00 03
CMuOC31>-T-;rHCMi-jOO'  ^
O^oicMcdlOi-HCOCD^cd 00 00 03 0 0 l>-00 03 03(0303
CM CO ^  
%  ^  ^
i) 03 Ôk  k  k
CM CO ^
Z Z Z 
iS tS (£CM CO ...................................% % % c 6 œ œ c ô O O O O
1>;03 03 03 0 0 CMC01—l l > - C M i —IC O
co3o6o6o6cdtqo3o6cocdoo600 00 00 0 0 D - D -0 0  00 O3 0 0 G O C 3
cqoqoooo3iLOOLOT-HiocM'^ 
o603T-5a3o6i—503C0»—iccJr-HLO 0 0 0 0 0 3 0 0 0 3 0 0 0 0 0 0 0 0 0 0 3 0 0
lOiiOCMLOLOiO^^OOOOC-t^   00 0003 03 03 03 Xfi00 00 OO 00 00 00 lO LO LO UO 03 03 03 03
CM CO rH
%
_(D CD _03 CD
k k k
r 4 CM CO 4
% ^  %
CM CO 1—1 CM COZ Z z  &
.03 03 CD 03
i
g
4-3CO
1
0
1
102 
r.0o
t
m
iO
CO
g
63
3. Homology Modelling of Rat CYP2D Enzymes
Metalloporphyrins have previously been successfully modelled using molecu­
lar mechanics. The co or dinative saturation of the iron within the porphyrin ring 
reduces the importance of the electrostatic effects, allowing for a more implicit 
model of electron behaviour, and results in relatively simple molecular geometries, 
such as square planar and octahedral, which require only two reference angles.
Overall, the CHARMM27 force field appears to provide a more consistent 
model of the rat cytochrome P450 2D1 haem group with those observed in both 
the crystal and idealised structures. Less deviation from the human CYP2D6 
structures is shown as is a lesser out-of-plane distortion of the transition metal 
iron. While the metalloporphyrins are easier to model using molecular mechanics 
techniques than other metalloproteins, this improvement of CHARMM27 over 
the AMBER99 force field is most likely due to the way these force fields handle 
bond angles.
The functional form of the AMBER force field is:
^total ^bond T  ^angle T  ^torsion T  ^non—bonded (3.1)
While the functional form of the CHARMM force field is:
^total ^bond~^ ^ angle~^ ^ dihedrals ^improperdihedrals~^ ^ Urey—Bradley ^non—bonded
(&2)
which includes a cross term to account for angle bending using 1, 3 non-bonded 
interactions;
^Urey—Bradley ^   ^ ^o) (3.3)
u
where ku is the force constant, u is the 1, 3 non-bonded distance and uq is the
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ideal bond distance.
This extra term allows CHARMM to model all bond angles with the standard 
harmonic Eangie function (Equation 3.4) bar those directly surrounding the tran­
sition metal where the Urey-Bradley cross term is used. This allows the metal to 
adopt geometries that are more favourable to the complex rather than limiting it 
to preconceived geometries calculated based on carbon hybridisation rather than 
transition metal geometries.
E a n g ie  = ' ^ ^ { 0  ~  Oq)^  (3.4)
e
3.4 Conclusion
While conventional molecular mechanics techniques for modelling protein struc­
tures, such as AMBER99 and CHARMM27, are not parameterised to model 
transition metals, the nature of the iron group present in cytochrome P450 en­
zymes gives us some leeway. The saturation of the coordinate geometry of the 
haem iron mixed with the use of a Urey-Bradley 1,3 non-bonded interaction term 
in the CHARMM force field provides us with a reasonable calculation for the 
haem. While there are more accurate tools available for the modelling of tran­
sition metals, the speed and efficacy of the CHARMM force field in modelling 
rat cytochrome P450 2D1, makes this a suitable choice for use in the homology 
modelling of the rat enzymes. The remaining rat cytochrome P450 2D enzymes 
were modelled under the CHARMM27 force field using the same steps described 
here for the models of rat cytochrome P450 2D1.
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Chapter 4 
M odelling Species Selectivity in 
Rat and Human Cytochrom e 
P450 2D Enzym es
4.1 Introduction
Three dimensional modelling approaches have been used to model the observed 
species selectivity of the pseudo enantiomers, quinidine and quinine, in rat and 
human CYP2D enzymes (see Chapter 1, Figure 1.1). Quinidine is observed to be 
a strong inhibitor of human CYP2D6, while quinine, although having little effect 
on human CYP2D6 metabolism is a strong inhibitor of rat CYP2D enzymes, es­
pecially rat CYP2D2 (see Chapter 1, Table 1.1).
Previous work modelling cytochrome P450 enzymes has been performed by 
Lewis, [34], while Zhang [35] has produced a machine learning model that shows 
a greater than 80% accuracy in predicting species selectivity. There have been 
many studies that have used quantitative structure activity relationships [34] 
to probe ligand binding but, like Lewis [34] and Zhang [35], these studies lack 
three dimensional information. Mulholland et al [77] have used the combined 
techniques of QM/MM to study the interactions with the iron in CYP, which 
is currently the highest level of modelling that can be achieved in proteins and
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they have been useful in describing the mechanistic details of the catalytic cycle. 
Venhorst et al [1] have generated homology models based on the x-ray structure 
of rabbit CYP2C5 and used this to identify 22 active site residues that are of 
importance in ligand binding. In this work we have based our models on the 
now available x-ray crystal structures of the human CYP2D6 which is a better 
starting point for the comparison. Computational techniques, such as homology 
modelling and molecular docking can be used to effectively investigate any se­
quence variation between species. This work describes a variety of techniques 
used to create homology models of rat CYP2D and to investigate the cause of 
species selectivity in rat and human enzymes.
Previous work on molecular recognition in antibodyiantigen interactions con­
cluded that the ability of antibodies to recognise a wide variety of ligands was not 
due to specific interactions with certain key selected amino acids but rather was 
due to a range of non-specific interactions in the overall active site [78]. CYP450s 
also show this inducible nature in responding to a wide variety of ligands. Our 
aim is to see if ligands, that differ only in their arrangement about two chiral 
centres, such as quinidine and quinine, show specific residue interactions or non­
specific binding.
4.2 Homology M odelling of Rat and Human CYP2D  
Enzymes
Using the methodology outlined in the previous chapter (see Chapter 3), homol­
ogy models of rat cytochrome P450 enzymes 2D 1-5 and 2D 18 were generated 
under the CHARMM27 force field based on both the available 2F9Q [8] and 
3QM4 [9] human CYP2D6 crystal structures. The models formed were analysed 
both visually and statistically within MCE [41] and molecular dynamics studies 
were performed in vacuo to confirm model stability using the NPT ensemble.
The homology models were analysed by Ramachandran plots (see for example 
Chapter 3, Figure 3.2) with 99% of the residues in allowed conformations and no
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outliers, providing confidence in the models used.
The x-ray crystal structure of prinomastat bound to cytochrome P450 2D6 
(3QM4) [9] was used to validate the docking procedure. The docking results 
showed that MOE was able to reproduce the crystal structure with an RMSD 
(Co) of 0.56Â and that prinomastat was in the vicinity of Ser304 and Glu216. 
There is no interaction in this crystal structure with Asp301, which has been 
proposed as a vital residue [79]. One of the major concerns in cytochrome P450 
modelling is the inducibility of the active site [80] i. e. if one compares the crystal 
structures of the native human CYP 2D 6 with the structure with prinomastat 
bound, there is a significant difference (increase in volume of 130Â^) in the active 
site. The active site of the ligand bound structure is larger but more closed, 
indicating that the protein has conformed to the shape of the ligand. Therefore 
we have carried out docking to both the homology models of the native enzyme 
and the ligand bound models.
4.3 Molecular Docking of Quinidine and Qui­
nine in Rat and Human CYP2D Enzymes
Using the available MOE [41] docking program, quinidine and quinine, known 
inhibitors of human CYP2D6, were docked in an active site defined from data 
available in literature [1] to both the haem and compound 1 forms of the human 
CYP2D6 crystal structures and the rat CYP2D homology models. In previous 
work from our group [60], results more consistent with experiment have been 
achieved by docking the x-ray crystal structure of the ligand rather than a model 
built up on an atom by atom basis. Therefore we have docked both the x-ray 
crystal structure and molecular model of quinidine [81] and the model of quinine 
as there is no crystal structure available.
Docking was initially performed using three methods; an alpha triangle rigid- 
protein-fiexible-ligand dock with a force field based refinement step and Lon­
don AG scoring function, an alpha triangle rigid-protein-rigid-ligand dock with
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a Gridmin based refinement step and London AG scoring function and a man­
ual placement and force field based minimisation step. As the force field based 
method caused some anomalies to occur with the aromatic rings of the ligands i. e. 
the loss of planarity in aromatic rings, the rigid Gridmin based docking method 
was used as this greatly reduced the number of observed anomalies in this case. 
The manual placement method was used to see if interaction with the haem iron 
was possible with these ligands. As these ligands are inhibitors and not substrates 
the Gridmin results are less subject to bias and none of these docks show a close 
approach to the iron.
Owing to the inducible nature of GYP 2D enzymes, a further energy min­
imisation step was then introduced into the docking analysis in order to more 
accurately model enzyme response. After docking, the protein was minimised 
under the GHARMM27 force field [58] around a fixed haem and docked ligand 
providing a representation of the induced docking model.
In each of the docks, the following information was recorded for each contact 
made with the protein (more than one in some cases):
• Residue types, number and subunit;
• Bonding type (backbone accept or/donor, H-bond acceptor/donor (side chain));
• Distance between donor and acceptor as calculated by MOE (Â); and
• Gontact point on the ligand according to the numbering scheme.
In a small number of cases anomalies in aromatic structure were observed 
during docking in which case a ligand optimisation script provided by MOE [41] 
was employed.
Ki values were calculated for each of the docked compounds for comparison 
with Ki values calculated from experimental JC50 values (see Ghapter 1, Table
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1.1). Ki values were calculated from AG using;
AG =  —RThiKeq
Kpn =
AG =  - R T \n - 1  (4.1)
Ki
ù,G = R T \n K i
rz ASKi = exp RT
4.4 Interaction Analysis of Quinidine and Qui­
nine in Rat and Human CYP2D Enzymes
More interactions with amino acid residues are observed in the vast majority of 
models (and for all models of quinine and the quinidine crystal structure) for those 
based on the 2F9Q crystal structure rather than the ligand bound 3QM4 crystal 
structure, indicating that the active site is smaller as discussed above. The close 
approaches (within 3.8Â) of quinine and the crystal and molecular structures of 
quinidine with amino acid residues in the rat and human models were recorded 
for each dock.
A rigid-protein-rigid-ligand dock was first performed of the quinidine crystal 
and molecular structures and quinine into all rat and human GYP2D models (see 
interaction analysis in Tables 4.1 and 4.2 and an example of this information 
shown pictorially in Figure 4.1. Further examples of these analysis diagrams can 
be seen in Appendix A.). For models based on the 2F9Q crystal structure no 
common interactions were found between quinine and the crystal and molecular 
structures of quinidine in all rat and human models. Quinine shows an interaction 
with residue 304 in all rat and human GYP 2D enzymes but this is not consis­
tent with the quinidine crystal structure as no interaction is observed with rat 
GYP2D18. Residue 216 was shown to interact with both human and rat models 
in the quinidine molecular and crystal structures but not in quinine, whereas qui­
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nine interacts with residues 220 and 308 in both human and rat models but not in 
the quinidine structures. Interactions that occur in both human and rat models 
indicate similar modes of binding. There are eight interactions with the human 
CYP2D6 model in the quinidine crystal structures and nine with the quinidine 
molecular structure but only seven in quinine. Of these only two are common, 
i.e. those interactions with 304 and 483. In the models based on 3QM4, residues 
216, 244, 300, 301 and 304 show interactions with both ligands in both human 
and rat structures with all rat and human models showing interactions with 301 
for quinine and all but CYP2D3 showing interactions with the quinidine crystal 
structure and all but CYP2D5 with the molecular structure. Human CYP2D6 
shows eleven observed interactions with the quinidine crystal structure, seven 
with the quinidine molecular structure and nine with quinine. Of these interac­
tions five are common; residues 216, 244, 300, 301 and 304.
Figure 4.1: Interaction diagram showing the rigid-ligand-rigid-protein dock of the 
quinidine crystal structure into the native haem form of the 2F9Q based model 
of CYP2D1. Predicted interactions are shown in blue.
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This docking was then repeated for the compound 1 forms of these models 
(Tables 4.3 and 4.4 and pictorially in Appendix A). For models based on the 
2F9Q structure, no common interactions were found to occur for both quinine 
and the crystal and molecular structures of quinidine in all rat and human mod­
els. Quinidine shows an interaction with residue 304 in all but rat CYP2D18 
in the quinidine crystal structure and rat CYP 2D 5 in the quinidine molecular 
structure. Residue 483 was found to interact with both rat and human models 
in quinine and the quinidine molecular and crystal structures. Residues 216, 301 
and 304 were found to interact with both human and rat models and the quinidine 
molecular and crystal structures but not quinine, whereas quinine interacts with 
residues 220, 308 and 373 in both human and rat but not quinidine. Again any 
interactions that occur in both human and rat models can indicate similar modes 
of binding. In this case there are eight interactions with human CYP 2D 6 and 
the quinidine crystal structure, nine interactions with the quinidine molecular 
structure and seven interactions between human CYP 2D 6 and quinine. Of these 
only one is common, i.e. residue 483. In the models based on 3QM4, no common 
residues are observed for all rat and human CYP 2D enzymes and quinine and 
quinidine. Interactions are observed between residue 120 in all rat and human 
CYP2D and quinine. Residues 120, 216, 301 and 304 show interactions with all 
ligands in both human and rat structures, residue 483 shows interactions between 
rat and human CYP 2D and the quinidine crystal and molecular structures while 
residue 213 shows interactions with both rat and human CYP 2D and quinine. 
There are eleven observed interactions with human GYP2D6 and the quinidine 
crystal structure, eight with the quinidine molecular structure and eight with 
quinine. Of these interactions five are common; residues 120, 216, 244, 301 and 
304.
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An energy minimisation step was then included to effectively model the in­
ducibility of cytochrome P450 enzymes. In these induced-fit docks (Tables 4.5 
and 4.6), models based on the 2F9Q structure, show interactions for all ligands 
with residue 304 in all rat and human CYP2D enzymes. Residues 213, 216 and 
301 are shown to interact with both human and rat models in quinidine but not 
quinine, whereas quinine interacts with 308 and 374 in both human and rat but 
not quinidine. There are ten interactions with the human CYP2D6 model and 
the quinidine crystal structure, nine with the quinidine molecular structure and 
seven in quinine. Of these only one is common to all ligands, i.e. those with 304. 
In the models based on 3QM4, residues 216, 244, 301 and 304 show interactions 
with both ligands in both human and rat structures with residue 301 showing 
interactions with all rat and human CYP2D enzymes and the quinidine crystal 
structure, all but rat CYP2D5 and the quinidine molecular structure and all but 
CYP2D2 with quinine. There are ten observed interactions with the quinidine 
crystal structure, nine interactions with the quinidine molecular structure and 
nine with quinine in human CYP2D6 with residues 216, 244, 301 and 304 being 
common to all ligands.
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For the compound 1 forms of the models based on the 2F9Q structure (Table 
4.7) no common interactions were observed for all ligands in all rat and human 
models. Residues 216, 301 and 304 are found to form interactions with the quini- 
dine structures only in rat and human CYP2D and quinine is found to form 
interactions with residues 220 and 308 in both rat and human. There are eight 
interactions with human CYP2D6 and the quinidine crystal structure, twelve 
with the quinidine molecular structure and six with quinine. Of these only two 
are common, residues 483 and 484. For the compound 1 forms of models based on 
3QM4 (Table 4.8), interactions are observed between residue 301 in rat and hu­
man CYP2D enzymes with all but CYP2D3 for quinine and all but rat CYP2D1 
with the quinidine crystal and molecular structures. Both quinidine structures 
show interactions with rat and human CYP2D enzymes at residues 209, 305 and 
484 but not quinine while quinine shows an interaction with residue 213 in rat and 
human but not quinidine. There are eleven interactions with human CYP2D6 
and the quinidine crystal structure, ten with the quinidine molecular structure 
and eight with quinine. Of these six are common, residues 120, 209, 216, 244, 
301 and 304.
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Previous work from our group [60] showed that the addition of crystallographic 
information to the compounds docked caused an improvement in results (Figure
4.2).
12
10
8
O  D  lOÜ
0 .4
0
- 65.00 - 60.00 - 55.00 - 50.00 - 45.00 - 40.00  - 35.00  - 30.00 - 25.00 
min Delta G
Figure 4.2: Figure taken from Tanczos et al. [60] showing a plot of pIC^o values 
against the minimum free energy of binding for atropine analogues docked into a 
model of the rat muscarinic receptor.
Both the quinidine crystal and molecular structures were therefore docked 
and analysed. The quinidine crystal structure, taken from Kashino and Haisa 
[81], shows quinidine to have a crystal structure with the common F2i space 
group. A comparison of the crystal and model structures shows an overall all 
atom RMSD value of 0.62Â. The structures were then compared to an idealised 
form of quinidine taken from a DFT optimisation of the quinidine crystal struc­
ture which showed an RMSD of 0.25Â and 0.63Â for the quinidine crystal and 
molecular structures respectively indicating that the quinidine crystal structure 
had not been modified extensively by crystal packing effects. Further investiga­
tion into the changes in bond length and angle shows variation throughout the 
quinidine structures (Figure 4.3 and Tables 4.9 and 4.10) with the DFT model of 
the quinidine crystal structure becoming more like that of the molecular structure. 
Investigation into the change in the torsion angle of C8-C13-C15-N16 further con­
83
4. Modelling Species Selectivity in Rat and Human CYP2D Enzymes
firms this with the quinidine crystal structure showing an angle of -161.7°, the 
quinidine molecular structure showing an angle of -153.2° and the quinidine DFT 
structure showing a change in the crystal structure angle to -155.5°.
19 23
3 1
Figure 4.3: Two-dimensional drawing of quinidine numbered by non-hydrogen 
atoms.
Using the experimental /C 50 values taken from Venhorst et a l [1] for CYPs 
2D1-2D4 and 2D6 a comparison was performed with the predicted free energy of 
binding (Figures 4.4 - 4.11). As you can see these results are inconclusive with 
the crystal structure showing a slight improvement in correlation in only a few 
cases.
The analysis was then performed for the quinidine crystal structure and qui­
nine alone. For the rigid-protein-rigid-ligand dock into the 2F9Q based models 
of rat and human cytochrome P450 2D, four common interactions of quinine and 
the quinidine crystal structure can be observed with the 2F9Q crystal structure 
of human CYP2D6, residues 213, 217, 304 and 483. For the 3QM4 based models 
five common interactions are once again observed, residues 216, 244, 300, 301 
and 304. For the compound 1 forms of the 2F9Q models, three common inter­
actions are observed, residues 217, 483 and 484 and six common interactions are 
observed for the 3QM4 based models, residues 120, 209, 216, 244, 301 and 304. In 
the induced-fit docks the 2F9Q based models show an increase in the number of
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Atom
Quinidine Crystal Structure Quinidine Molecular Structure Quinidine DFT Structure
Bond Lengths /  A Bond Lengths /  A Bond Lengths /  A
N1-C2 1.31 1^8
C&C3 1.41 1.40 1.42
C&C4 1.36 1.40 1^8
C 4 € 5 1.41 1.40 1.42
C&C6 1^8 1.41 1.39
C&C7 1.40 1.41 1.42
CTC8 1.43 1.43 1.44
C&C9 1.36 1.42 1^8
C9-C10 1.41 1.40 1.42
ClO-Nl 1.31 1.30 1.33
C5-011 1.36 lj& 1.39
011-C12 1.41 1.41 1.46
C8-C13 1.53 1.53 1.52
C13-014 1.42 1.43 1.47
C13-C15 1.53 1.56 1.55
C15-N16 1.49 1.50 1.49
C15-C20 1.54 1.57 1.57
N16-C17 1.47 1.50 1.49
N16-C22 1.48 1.51 1.50
C17-C18 1.54 1.59 1.58
C18-C19 1.53 1.55 1.56
C19-C20 1.53 1.57 1.55
C19-C21 1.52 1.57 1.55
C21-C22 1.55 1.58 1.56
C18-C23 1.50 1.51 1.51
C23-C24 1.26 1.35 1.34
Table 4.9: Bond lengths (Â) for all quinidine struct rues.
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Atom
Quinidine Crystal Structure Quinidine Molecular Structure Quinidine DFT Structure
Bond Angles /  ° Bond Angles /  ° Bond Angles /  °
C7-C2-C3 119.3 120.3 119.4
C10-N1-C2 116.3 123.5 117.8
N1-C2-C3 117.5 118.6 117.6
N1-C2-C7 124.2 121.1 123.0
C2-C3-C4 121.4 120.4 121.2
C2-C7-C8 117.8 117.7 117.2
C3-C4-C5 119.8 120.3 119.3
C4-C5-C6 119.7 119.7 121.1
C4-C5-011 123.9 120.0 123.1
C5-011-C12 120.2 109.1 119.4
C5-C6-C7 121.7 121.2 120.6
C6-C5-011 116.4 120.1 115.8
C6-C7-C8 124.2 124.1 124.3
C6-C7-C2 118.0 118.1 118.3
C7-C8-C9 117.9 117.0 117.9
C7-C8-C13 121.3 122.9 MI&8
C8-C9-C10 120.0 120.2 120.8
C9-C10-N1 124.7 120.5 123.1
C9-C8-C13 120.8 119.8 118.5
C8-C13-C15 109.2 111.1 114.3
C8-C13-014 110.9 110.0 108.2
014-C13-C15 110.8 114.3 108.9
C13-C15-N16 112.6 113.9 112.5
C13-C15-C20 113.6 116.2 112.9
C15-N16-C17 107.6 110.8 108.3
C15-N16-C22 111.2 109.1 112.3
N16-C17-C18 112.4 112.1 111.4
C17-N16-C22 107.7 108.6 109.3
C17-C18-C19 106.8 108.0 106.6
C17-C18-C23 110.6 112.0 112.5
C18-C23-C24 127.3 122.7 125.0
C18-C19-C20 108.1 109.6 111.2
C18-C19-C21 109.9 106.5 108.1
C19-C18-C23 113.7 112.1 113.5
C19-C20-C15 108.5 110.5 108.4
C19-C21-C22 108.4 110.3 107.8
C20-C15-N16 110.1 109.4 109.6
C20-C19-C21 108.2 107.9 108.0
C21-C22-N16 110.9 110.6 110.9
Table 4.10: Bond angles (°) for all quinidine structures.
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Figure 4.4: The observed correlation between the predicted free energy and ex­
perimental pIC^o of both the quinidine crystal and molecular structures when 
docked into both the haem only and compound 1 active sites of the 2F9Q based 
models of CYPs 2D1-2D4 and 2D6.
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Figure 4.5: The observed correlation between the predicted free energy and exper­
imental pIC^o of both the quinidine crystal and molecular structures when docked 
into both the haem only and compound 1 forms of the 3QM4 based models of 
CYPs 2D1-2D4 and 2D6.
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Figure 4.6: The observed correlation between the predicted free energy and ex­
perimental pIC^o of both the quinidine crystal and molecular structures for the 
haem forms of both the 2F9Q and 3QM4 based models of CYPs 2D1-2D4 and 
2D6.
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Figure 4.7: The observed correlation between the predicted free energy and ex­
perimental pIC^o of both the quinidine crystal and molecular structures for the 
compound 1 forms of both the 2F9Q and 3QM4 based models of CYPs 2D1-2D4 
and 2D6.
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Figure 4.8: The observed correlation between the predicted free energy and ex­
perimental p/Cso of both the quinidine crystal and molecular structures in the 
haem forms of the 2F9Q based models of CYPs 2D1-2D4 and 2D6.
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Figure 4.9: The observed correlation between the predicted free energy and ex­
perimental p/Cso of both the quinidine crystal and molecular structures in the 
compound 1 forms of the 2F9Q based models of CYPs 2D1-2D4 and 2D6.
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Figure 4.10: The observed correlation between the predicted free energy and 
experimental pIC^o of both the quinidine crystal and molecular structures in the 
haem forms of the 3QM4 based models of CYPs 2D1-2D4 and 2D6.
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Figure 4.11: The observed correlation between the predicted free energy and 
experimental pIC^o of both the quinidine crystal and molecular structures in the 
compound 1 forms of the 3QM4 based models of CYPs 2D1-2D4 and 2D6.
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common interactions to four, residues 217, 220, 304 and 373 and the 3QM4 based 
models show an increase to seven common interactions, residues 120, 216, 244, 
301, 304, 309 and 484. For the compound 1 forms an increase to three common 
interactions is observed for the 2F9Q based models, this time residues 217, 483 
and 484, while for the 3QM4 based models an increase to six common interactions 
is observed, residues 120, 209, 216, 244, 301 and 304.
For the quinidine molecular structure and quinine, three common interactions 
are observed with the 2F9Q based rigid-protein-rigid-ligand docks, interactions 
with residues 304, 305 and 483. As with the quinidine crystal structure, interac­
tions are observed with residues 216, 244, 300, 301 and 304 in the 3QM4 based 
models. For the compound 1 forms of the 2F9Q models, one common interaction 
is observed, residue 483, and five common interactions are observed for the 3QM4 
based models, residues 120, 216, 244, 301 and 304. In the induced-fit docks the 
2F9Q based models show two common interactions with residues 304 and 483 and 
the 3QM4 based models show an increase to six common interactions, residues 
120, 216, 244, 300, 301 and 304. For the compound 1 forms, four common in­
teractions are observed for the 2F9Q based models, this time residues 213, 373, 
483 and 484, while for the 3QM4 based models seven common interactions are 
observed, residues 120, 209, 213, 216, 244, 301 and 304.
Previous work on the docking of quinine and quinidine using the models based 
on the rabbit x-ray crystal structure [1] indicated that quinidine interacted with 
Asp301, Ser304 and Phel20 in the human model and could not approach Asp301 
as closely in the rat CYP2D2 model but formed a hydrogen bond to the main 
chain of Met304 (which replaces Ser304 in 2D2). In this work, interactions be­
tween CYP2D2 and Asp301 are found for models based on 2F9Q with the energy 
minimisation step showing a movement of the Met304 side chain to allow for 
interaction between the quinidine crystal structure and Asp301. The compound 
1 form of the 2F9Q based model appears to overcome this problem as the ad­
ditional oxygen group helps shift the docked quinidine crystal structure into a 
position such that it can interact with Asp301 during the rigid-protein-rigid- 
ligand dock. For those models based on both the haem and compound 1 forms of
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3QM4 the Met304 side chain is already in a position which allows for interaction 
with Asp301.
Interactions are consistently observed between the quinidine crystal structure 
and residue 304 for models based on 2F9Q with all but CYP2D18 showing in­
teractions in both the rigid and induced fit docks of the haem and compound 1 
forms. In the induced fit dock, based on the haem form of 2F9Q, interactions 
were observed between all CYP2D and residue 304. Interactions were observed 
between the quinidine molecular structure and residue 304 in the majority of 
cases for models based on 2F9Q with no interactions being observed with rat 
CYP2D5 in either case of the compound 1 docks. For models based on 3QM4 
this interaction is less commonly observed with either of the quinidine structures. 
Interactions with the quinidine crystal structure are observed with all but CYPs 
2D1, 2D3 and 2D5 in the 3QM4 haem models and with all but CYPs 2D2 and 
2D5 in the compound 1 forms. For the quinidine molecular structure, interac­
tions with residue 304 are observed consistently with CYP2D6 but interactions 
are not observed with CYPs 2D2, 2D3 and 2D 18 in any of the haem docks with 
the rigid-protein-rigid-ligand dock also failing to show interactions with CYPs 
2D1 and 2D4. For the compound 1 forms, interactions are consistently observed 
with CYPs 2D2, 2D4 and 2D6 with the induced-fit dock also showing interactions 
with CYPs 2D3 and 2D 18.
As in Venhorst et al interactions were observed between the quinidine crystal 
structure and residue Phel20 of the 2F9Q crystal structure of human CYP2D6 
with the energy minimisation step moving the aromatic ring into proximity with 
the docked quinidine. Again, the addition of the double bond oxygen in the com­
pound 1 form appears to allow the quinidine to dock more closely within this 
region of the active site. For the 3QM4 based models, an interaction with V ail20 
is consistently observed in rat CYP2D2. For the quinidine molecular structure 
the energy minimisation step is once again observed to facilitate an interaction 
with residue Phel20 in both the haem and compound 1 forms of the 2F9Q based 
models with the 3QM4 based compound 1 model appearing to overcome this 
problem. In this case interactions are not observed with Vail20 in any of the rat
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CYP2D2 models.
In the previous work on the quinine docking [1], interactions were found with 
the carbonyl backbone of 301 in the human model and to Asp216, Thr217 and 
Met304 in the rat CYP2D2 model. Interactions were found with the backbone 
and side chain of Asp301 with only the 3QM4 human structures. Interactions 
with Asp216 were observed with all 2F9Q based models of rat CYP2D2 and all 
but the rigid-protein-rigid-ligand dock into the compound 1 form of the 3QM4 
based structure. No interactions were observed with Thr217 in any case. Interac­
tions were also consistently observed between rat CYP2D2 and Met304 in models 
based on both 2F9Q and 3QM4.
In literature [1], interactions with human Glu216 are often found, in this 
work interactions are also commonly observed between quinidine and residue 216 
in both human CYP2D6 and rat CYPs 2D2 and 2D3 based on both the haem 
and compound 1 forms of the 2F9Q crystal structure with the exception of the 
induced fit dock of the quinidine molecular structure. For models based on 3QM4 
interactions with residue 216 are observed with human CYP2D6 and rat CYPs 
2D4 and 2D 18. Interactions are also observed between residue 216 and quinine in 
the 3QM4 based models of CYPs 2D4, 2D5, 2D6 and 2D18 and the 2F9Q based 
models of CYPs 2D2 and 2D3.
Experimental binding data for human CYP2D6 (see Chapter 1, Table 1.1) 
shows quinine binds approximately 1000 times less well than quinidine. In both 
the 2F9Q and 3QM4 based models of human CYP2D6, more interactions were ob­
served for quinidine than quinine with two exceptions; the dock of the quinidine 
molecular structure into the rigid-protein-rigid-ligand dock of the haem 3QM4 
crystal structure and the induced fit docks of the quinidine crystal structure, 
which is consistent with the type I binding spectrum observed by Ellis et al. 
[82, 83] for quinidine. However, the experimental binding situation is reversed 
in the rat CYP2D2 where quinine binds approximately 1000 times tighter than 
quinidine. Here the quinine should theoretically make more contacts with the 
protein. This is seen in the 3QM4 model where all but the induced fit dock of
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the quinidine molecular structure into the compound 1 form shows more contacts 
for quinine than quinidine. In fact, these results follow the experimental data 
in the majority of cases of the 2F9Q based models with more interactions being 
observed for the more potent isomer for all quinidine structures but the haem 
docks into CYP2D2 and the rigid-protein-rigid-ligand dock into CYP2D18. The 
3QM4 based models are less consistent with the induced fit docks into the com­
pound 1 forms of CYPs 2D1, 2D2 and 2D4 and the rigid haem dock of CYP2D5 
failing to show more interactions for the more potent isomer for either quinidine 
structure. Comparison of the quinidine molecular and crystal structures shows 
that the molecular structure gives the correct, more potent isomer in more cases 
(38 out of 56) than that of the crystal structure (34 out of 56).
If the lowest energy docking results are considered (Table 4.11), in models 
based on the 2F9Q structure for the CYP2D6 case the quinidine crystal struc­
ture has a higher predicted pKi (the logarithm of the inhibitory constant) than 
quinine, 9.7702 to 8.0578, and a lower free energy of binding, -13.3215 to -10.9646 
kcal/mol. The results are reversed when the quinidine molecular structure is com­
pared to the quinine model structure, indicating that there is some advantage in 
using the crystal structure in this case. This does not follow in the compound 1 
case where quinine shows the highest predicted 7.5243, and the lowest free 
energy of binding, -11.7404 kcal/mol suggesting that the addition of the oxygen 
group does not improve the docking results. For the models based on the 3QM4 
structure, quinidine (crystal or molecular structure) has a higher pKi and a lower 
free energy of binding than quinine in both the haem and compound 1 forms. 
Overall the results are consistent with experimental results for CYP2D6 however 
this is not true for CYP2D2 where quinine shows the lowest pKi and highest free 
energy of binding in all cases. Therefore, in the case of simulated inhibitory con­
stants and binding free energies, the models based on the native haem are more 
consistent with experiment. In the previous work [1], the differences in binding 
efficiency between the isomers were ascribed to the difference in close approach to 
the iron atom in the haem. However, it was stated that the ligands were located 
close to the haem in this work but that this was not a requirement for all com­
petitive inhibitors, like these ligands, and multiple binding modes are possible.
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These large differences in experimental binding efficiency cannot be prescribed 
wholly to small differences in interaction energies so, as in the antibodyiantigen 
case, it is the sum total of the weak interactions overall that accounts for the 
inducible nature of CYP450 binding and this is true in the quinine:quinidine case 
also. The large non-specific binding site of CYP450 is ideally suited to binding a 
wide variety of ligands.
In ligands with polar groups prominent there is an interaction observed with 
the iron of the haem in the protein. This is consistent with the x-ray results for 
prinomastat which shows a Fe-N interaction with the pyridinyl ring. However, 
we do not observe a close approach to the iron in the majority of our docking 
studies. In the case of quinidine, this is consistent with experimental data taken 
from Hutzler et al [33] which shows quinidine to have a type I binding spec­
trum, suggesting that quinidine displaces the water in the sixth coordination site 
rather than ligating to the haem iron (type II). For quinine, a close approach 
is observed for the rigid-ligand-rigid-protein dock into the 3QM4 structures of 
human CYP2D6 and rat CYP2D4 which is, again, consistent with experimental 
data showing quinine to have a type II binding spectrum [33] in human CYP2D6, 
but not in any other cases.
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4.5 Conclusion
The basis of species selectivity in human and rat cytochromes is a complex prob­
lem, which demonstrates clearly how non-specific binding can be used in nature 
to engineer proteins that are able to bind to a wide variety of substrates. The 
results in this chapter show that models based on the smaller, more open active 
site in the 2F9Q structure are better models of the observed experimental data 
for quinidine and quinine than those based on the larger closed 3QM4 structure 
and that there are differences in both the number of interactions made by differ­
ent ligands as well as their close approaches and it is important to take this into 
account when seeking to understand their binding. The haem forms of the models 
produced appear to more closely follow the experimental data than those models 
based on the compound 1 forms, especially in the case of the predicted binding 
free energy which shows no agreement with the experimental results in any case. 
The use of crystallographic information in the docked compound does not appear 
to have a significant impact on the docking results with a slight improvement 
being observed only during the interaction analysis.
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Chapter 5 
Docking Topology of Substrates 
and Inhibitors in Rat and Human  
Cytochrom e P450 2D Enzymes
5.1 Introduction
Three dimensional modelling approaches were used previously to model the species 
selectivity observed for quinidine and quinine in rat and human CYP2D en­
zymes. It was concluded that as described by MacCallum [78] in relation to an­
tibodyiantigen interactions, molecular recognition of a wide variety of substrates 
in CYPs is due not to specific interactions with certain key selected amino acids 
but rather to a range of non-specific interactions in the overall active site [84]. 
Further research into the three dimensional position is therefore required, with re­
search being carried out into the effect of docking topology on species selectivity. 
Previous work by Teng [85] on the identification of a common docking topology 
in different T Cell Receptor-peptide-Major Histocompatibility complexes (TCR- 
pMHC), along with further work in the same area by Wang [86] and Adams [87], 
showed substantial variation in the individual docking position but an overall 
common docking topology. As with cytochrome P450 enzymes, T-cell receptors 
are able to form complexes with a wide variety of pMHC ligands, the number of 
which largely exceeds the number of T-cell clones available in the human body
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but also similarly use the induced-fit model to explain the observed structural 
differences between free and complexed antibodies. Using computational tech­
niques, such as homology modelling, molecular docking and surface analysis we 
have investigated the binding interactions formed and docking positions observed 
for a series of well-known CYP2D6 substrates and inhibitors and by applying this 
theory of an overall docking topology we have found some noticeable variation in 
the docking topology of substrates when compared to inhibitors.
5.2 Molecular Docking of Rat CYP2D Enzymes
Using the models created previously, eight known inhibitors, including quini­
dine and quinine, and seven known substrates of human cytochrome P450 2D6 
(see Chapter 2, Figure 2.3) were docked into both the human CYP2D6 crystal 
structures [8, 9] and the rat CYP2D homology models using the available MCE 
docking program [41]. As there was no apparent benefit in using the molecular 
structure over that of the crystal structure, only the quinidine crystal structure 
has been docked here (see Chapter 4).
Docking was once again performed using a rigid-protein-rigid-ligand dock with 
a Gridmin based refinement step and London AG scoring function. An additional 
energy minimisation step under the CHARMM27 force field [58] is used to model 
the inducible nature of the CYP2D enzymes. A small number of cases showed 
distortion of the aromatic structure during docking and the ligand optimisation 
script [88] was employed. A combination of the 3D ligand interaction prediction 
and 2D ligand interaction tool from MCE [41] was used to predict and visualise 
protein-ligand interactions likely to occur for each of the compounds docked.
A further forty known inhibitors and substrates (Figure 5.1) of human cy­
tochrome P450 2D6 were docked into both the human CYP2D6 crystal structures 
[8, 9] and the rat CYP2D homology models and their compound 1 forms, using 
the available MCE [41] virtual screening program. The virtual screen was per­
formed using a rigid-protein-rigid-ligand dock with a London AG scoring function 
and no refinement step.
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For each compound docked, the orientation was measured as the angle of 
a plane relative to the haem iron (Figure 5.2) and recorded for all the lowest 
energy, highest energy and mid-point docks of each substrate and inhibitor and 
their orientation assigned using the following rule;
I{x) =
Parallel if z < 135' 
Normal if T > 135'
Figure 5.2: Orientation of quinidine docked in human CYP2D6 (2F9Q). The 
orientation is measured as the angle of a plane from the haem iron to the furthest 
atom.
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5.2.1 Inhibitor Docking into Rat and Human CYP2D En­
zymes
As previous work (see Chapter 4) has suggested a relationship between quini- 
dine/quinine potency and the number of non-specific binding interactions formed, 
implying that the inducibility of cytochrome P450 enzymes is not due to the for­
mation of specific interactions, further investigation into inhibitor docking was re­
quired. Six inhibitors (see Chapter 2, Figure 2.3 excluding quinidine and quinine) 
of varying potency were docked into the crystal structures of human CYP2D6 
and the models of rat CYP2D and their interactions recorded. Some common 
interactions were observed for these inhibitors. In the models based on the na­
tive CYP2D6 crystal structure (PDB: 2F9Q [8]), no common interactions were 
observed across both species or for the human models alone but eighteen inter­
actions with amino acids were observed across the rat models i.e. residues 52, 
55, 102, 112, 221, 224, 248, 297, 312, 369, 372, 375, 399, 480, 481, 482, 484, 486. 
Four residues were found previously [84] to interact with rat and human enzymes 
in quinidine but not quinine, residues 213, 216, 244 and 301. In this case, only 
residue 301 was found to interact with all inhibitors bar quinine. Residue 216 was 
also shown to interact in the majority of cases with only quinine and amiodarone 
interacting with rat CYPs only. Interactions were also found between residues 
308, 374 and 483 and quinine in both rat and human models but not with quini­
dine, however these interactions no longer appear consistent with all inhibitors.
For models based on 3QM4, one common interaction was observed in both 
species, residue 304, two common interactions were observed for the docks in 
human CYP2D6, 211 and 226, and twenty-five interactions were observed across 
the rat CYP2D enzymes i.e. residues 54, 103, 111, 117, 222, 225, 243, 247, 248, 
296,297,367,368,369,370,372,373,374,375,435,481,482,483,484. (3f these 
common rat interactions only seven are common to both sets of models. Previ­
ously [84], four residues were found to form interactions with both quinidine and 
quinine in rat and human CYPs, residues 216, 244, 301 and 309. Residue 301 
again shows interactions with almost all rat and human CYPs with only quinine 
and bupropion showing no interactions in CYP2D2 and CYP2D18, respectively.
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Ligand Experimental k* (^M)
Human CYP2D6 (2F9Q) Human CYP2D6 (3QM4)
Interaction Count Interaction Count
Quinidine 0.064 10 9
Cinacalcet 0.087 10 9
Terbinafine 0.030 8 8
Buprenorphine 10 9 8
Quinine 13 7 9
Bupropion 21 7 7
Cimetidine 3 8 7 6
Amiodarone 45 11 9
Table 5.1: Number of interactions formed in the binding site compared to their 
experimental Ki values [89-95].
Residue 216 continues this trend, with interactions observed for both human and 
rat CYPs with all but bupropion and cimetidine. An interaction with residue 
120 was also commonly observed in both rat and human CYPs, further implying 
that the observed cytochrome P450 inducibility is due to a number of non-specific 
binding interactions and not any one specific interaction (Table 5.1).
These residues 301, 216 and 120 have long been considered important for sub­
strate binding in cytochrome P450 2D6 [27, 28, 96] and as shown here also play 
a key role in inhibitor binding. Previous work by Sutcliffe et al [28] showed that 
mutation of Glu216 and Asp301 to residues without a negative charge greatly 
reduced the inhibitory effect of quinidine while a similar mutation of Phel20 
to the non-conservative amino acid residue alanine showed only a minor effect 
on the inhibitory strength of quinidine. In fact the F120A mutant and the 
E216Q/D301Q double mutant were shown to form both 3-hydroxyquinidine and 
0-demethylquinidine, two metabolites of quinidine. Similar results have been 
observed by Zhou et al [97] and Hutzler et al [33].
5.2.2 Substrate Docking into Rat and Human CYP2D  
Enzymes
This hypothesis was then extended to investigate the effect on substrate recog­
nition and binding. Seven well-known substrates of human CYP2D6 (see Chap­
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ter 2, Figure 2.3) were docked under the same conditions used previously and 
the best models chosen, based on literature data of the metabolic route. These 
substrates were chosen to show examples of both the common substrate phar­
macophore with the site of oxidation located 5 - 7Â from the basic nitrogen e.g. 
5-Methoxytryptamine and the novel binding mode of pactimibe which has no 
basic nitrogen and a site of metabolism at the cu-carbon far from the aromatic 
moiety [25]. In this case, a close approach to the haem iron was observed further 
supporting the previous assertion that this is not a requirement for inhibitors 
[84]. Interaction analysis was again performed, with common interactions being 
observed for rat and human in both models. In models based on 2F9Q, two 
common interactions were observed across species, 300 and 374; four common 
interactions in human alone; 120, 218, 480, 482 and five common interactions in 
rat; 220, 244, 312, 369, 484. In models based on 3QM4 no common interactions 
were observed for human alone but three were observed across species; 216, 304, 
308 and thirteen in rat alone; 112, 212, 213, 312, 369, 370, 372, 373, 374, 435, 482, 
483, 484. Once again, no overall common interactions were observed. Pactimibe, 
with its unusual binding mode was only observed in the active site of the 2F9Q 
[8] crystal structure of human CYP2D6.
Residues 301, 216 and 120 are all considered important for substrate bind­
ing [28] and while no common interactions are consistently observed for these 
residues in the 3QM4 case, interactions are observed for the majority of sub­
strates. Residue 216 shows interactions in both species for all substrates and 
residue 301 for all but MPTP where only interactions with rat CYPs 2D1, 2D4 
and 2D 18 are observed, and 5-Methoxytryptamine where interactions are ob­
served with human CYP2D6 alone. In both the 2F9Q and 3QM4 based models 
interactions are also consistently observed for the majority of substrates with 
residue 483, another residue identified as being important to substrate binding 
[96].
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5.2.3 Effect of Docking Topology on Substrate and In­
hibitor Docking into Rat and Human C Y P2D  En­
zymes
Further investigation into the behaviour of inhibitors and substrates in CYP2D 
enzymes was then performed. A great deal of variation was observed in the di­
rectionality and topology of the substrates and inhibitors docked in the active 
site. Surface analysis showed a distinct difference in the overall placement of the 
substrates and inhibitors relative to the haem group (Figures 5.3 and 5.4). In 
the majority of cases, for models based on both the 2F9Q and 3QM4 structures, 
inhibitors were found to dock parallel to the haem group, lying across the active 
site and effectively blocking access to the haem, while substrates were found to 
dock normal to the haem group, moving down through the centre of the active 
site. Figures 5.5 and 5.6 show the observed variation in orientation between the 
inhibitors and substrates in both crystal structures of CYP2D6.
The investigation was then repeated as a virtual screen for both the CYP2D 
models described above and their compound 1 forms with 10 poses being retained 
for each compound. In the compound 1 case, the angle is still measured relative 
to the haem iron as the docking will have already accounted for any effects of 
oxygenation. For quick analysis the ligand orientations were recorded for only the 
lowest, highest and mid-point energy docks. For models based on both the 2F9Q 
and 3QM4 crystal structures, the mid-point energy dock was the most consistent 
with the hypothesis and will be used in any further analysis.
For the 2F9Q based models, 40% of substrates were found with an orientation 
angle greater than 135° and 78% of inhibitors were found in an orientation less 
than 135° giving an average overall agreement with the hypothesis of 61% for the 
haem models. Analysis of the variance (ANOVA) of this angle gave a probabilty 
value of 0.22 which while not significant (as defined by a P-value <0.05) for this 
small data set could be improved with further refinement of this simple predictive 
model and the use of a larger data set. The compound 1 forms showed 44% of 
substrates with a >135° orientation angle and 91% of inhibitors with a <135°
107
5. Docking Topology of Substrates and Inhibitors in Rat and Human
CYP2D
Figure 5.3: Example of substrate and inhibitor docking topology in the 2F9Q 
crystal structure of human CYP2D6 [8]. The substrate MPTP is shown in red 
and the inhibitor cimetidine in blue.
Figure 5.4: Example of substrate and inhibitor docking topology in the 3QM4 
crystal structure of human CYP2D6 [9]. The substrate MPTP is shown in red 
and the inhibitor cimetidine in blue.
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Figure 5.5: Surface analysis of all successful substrate and inhibitor docks in the 
2F9Q crystal structure of human CYP2D6 [8]. The binding site surface area is 
shown in white with the substrate surace area in red and the inhibitor surface in 
blue.
M
Figure 5.6: Surface analysis of all successful substrate and inhibitor docks in the 
3QM4 crystal structure of human CYP2D6 [9]. The binding site surface area is 
shown in white with the substrate surace area in red and the inhibitor surface in 
blue.
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orientation angle giving an average overall agreement of 70%, however, in this 
case ANOVA variance analysis gives a predicted P-value of 0.54 indicating that 
this rule could not be used with confidence for both the compound 1 and haem 
structures.
For models based on 3QM4, 37% of substrates showed a >135° orientation 
angle and 75% of inhibitors had a <135° orientation angle giving an average over­
all agreement of 57% for the haem models. Again this decrease in effectiveness is 
seen in the ANOVA variation analysis which gives a P-value of 0.41. For the com­
pound 1 model, however, these result increase to 39% of substrates with angles 
>135°, 81% of inhibitors with angles <135° and an average overall agreement of 
59%. ANOVA, in this case shows significance at the 10% level with a P-value 
of 0.10. Previous work from Vermeulen et al. [96] showed that the accuracy of 
virtual screening was dependent on the docking and scoring combination used 
with hit rates and yields being generally low. In this study, docking with the 
FlexX-Dock docking-scoring pair resulted in hit rates and yields of only 12% and 
30% repectively. Docking with the GOLD-Goldscore combination gave a maxi­
mum yield and hit rate of 4% and 10% with the GOLD-Ghemscore combination 
performing best with a yield of 24% and a hit rate of 60%. The early stage results 
shown here are comparable and with further refinement, could provide a quick 
and easy technique for the prediction of a drug’s action in the cytochrome P450 
2D enzyme family.
5.2.4 Validation of the Effect of Docking Topology on 
Substrate and Ligand Binding to Rat and Human  
CYP2D Enzymes
A preliminary validation was then performed using a set of twenty substrates and 
twenty inhibitors of CYP2D6 (Figure 5.1). Again, for models based on both the 
2F9Q and 3QM4 crystal structures, the mid-point energy dock showed the most 
agreement with the hypothesis. For the 2F9Q based models, an overall agreement 
of 56% was found for the haem models and an agreement of 54% was recorded for
1 1 0
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compound 1. This was improved very slightly for models based on 3QM4 with 
the haem set showing an overall agreement of 64% and the compound 1 forms 
showing an agreement of 51%. Unfortunately due to time constraints it was not 
possible to perform ANOVA for these results.
As a further test of this hypothesis, a number of existing non-mutated ligand 
bound crystal stuctures of common cytochrome P450 enzymes were investigated; 
CYPs lA l, 1A2, 2D6, 2C9 and 3A4. In just over two thirds of cases investigated, 
the ligands bound were inhibitors which showed an agreement with the hypoth­
esis of 65%. In the remaining substrate cases an agreement of 67% was observed 
giving an overall agreement of 65% which is a slight improvement on the accuracy 
of prediction observed in the majority of docking simulations.
The angles of orientation were recorded and compared to their experimental 
IC 5 0  values for all docked quinidine and quinine models in rat and human CYP2D 
(Table 5.2). In this case, the more potent isomer was observed to have a relative 
orientation closer to the ideal orientation of 90° for all haem models with the 
exception of the 2F9Q based model of CYP2D2, and for all compound 1 models 
with the exceptions of both the 2F9Q and 3QM4 based models of CYP2D3 and 
the 3QM4 based model of CYP2D1.
Overall, this suggests that the angle of orientation correctly predicts the more 
potent isomer four times out of five, a percentage accuracy of 64% on par with the 
accuracy found for existing ligand bound crystal structures. Comparing this with 
the accuracy of prediction of the London AG scoring function used by MOE-Dock 
[41], which correctly predicts the more potent isomer 44% of the time (Table 5.3), 
we can see significant improvement.
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CYP2D5 CYP2D18 CYP2D5 CYP2D18
Ligand 2F9Q 2F9Q - Compound 1
Orientation Angle /  ° Orientation Angle /  ° Orientation Angle /  ° Orientation Angle /  °
Quinidine 8&8 93.7 9&0 134.7
Quinine 106.9 92.0 9&8 133.9
3QM4 3QM4 - Compound 1
Quinidine 108.1 105.1 127.4 76.9
Quinine 134.1 87.0 129.2 88.7
Table 5.4: Recorded orientation angles for all docked quinidine and quinine in 
rat CYP2D5 and CYP2D18.
A prediction of the more potent isomer was then made for the models of 
CYP2D5 and CYP2D18 for which there is currently no available experimental 
binding information (Table 5.4). While these angle differences are very small, 
for an ideal inhibitor orientation of 90°, quinidine was predicted to be the more 
potent isomer for all models of CYP2D5 based on 2F9Q and 3QM4 and quinine 
the most potent for all models of CYP2D18.
Previously, we suggested that the 2F9Q structure provides a better basis upon 
which to model species selectivity, with the smaller more open active site in 
the 2F9Q structure more accurately modelling the observed experimental data 
for quinidine and quinine than those based on the larger closed 3QM4 crystal 
structure. In this case, we see a slight improvement in results when using the 
3QM4 based structure rather than that of the 2F9Q. More common interactions 
were observed across species for all substrates and inhibitors when docked into 
models based on 3QM4 and an improved agreement with the docking topology 
hypothesis was observed in the validation set.
5.3 Conclusion
The basis of species selectivity in human and rat cytochromes is a complex prob­
lem which demonstrates clearly how non-specific binding can be used in nature 
to engineer proteins that are able to bind to a wide variety of substrates. This 
preliminary work suggests that for cytochrome P450 enzymes, potent substrates 
and inhibitors could be identified at an earlier stage of drug development through 
some form of placement analysis within the active site regardless of species or
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stereochemistry. While the anaylsis performed here is not currently fully pre­
dictive, showing promise only in the haem 2F9Q and compound 1 3QM4 cases, 
further work into both the prediction rules and the use of larger data sets could 
help create a quick and effective prediction methodology.
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Chapter 6
Identification and Analysis of 
Residues Responsible for a 
Change of Potency in Quinidine 
and Quinine
6.1 Introduction
An investigation into the active site placement of substrates and inhibitors has 
revealed a great deal of variation in the directionality and topology of the docked 
compounds. Surface analysis showed a distinct difference in the overall placement 
of the substrates and inhibitors relative to the haem group (see Chapter 5). In 
the majority of cases, for models based on both the 2F9Q and 3QM4 structures, 
inhibitors were found to dock parallel to the haem group, lying across the ac­
tive site, co-opting key amino acid residues and effectively blocking access to the 
haem, while substrates were found to dock normal to the haem group, moving 
down through the centre of the active site. This suggests that for cytochrome 
P450 enzymes, potent substrates and inhibitors can be identified at an early stage 
of drug development through placement analysis within the active site regardless 
of species or stereochemistry.
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A prediction methodology has therefore been created which allows for early 
stage prediction of a compound’s enzyme behaviour. Using this tool, a prediction 
has been made of the inhibitory potency of quinidine and quinine in rat CYPs 2D5 
and 2D 18 for which no experimental binding information currently exists. Pre­
vious studies [28, 96] have suggested the importance of human CYP2D6 residues 
AspSOl, Ser304, Clu216 and Phel20 to enzyme function. While interactions with 
these residues have been consistently observed throughout this work, there is no 
apparent connection between these residues and the change in potency observed 
with quinidine and quinine in rat and human CYP2D enzymes. Using this pre­
diction, a second sequence analysis has been performed and three residues with 
a possible effect on potency have been identified. Molecular docking techniques 
have been used to investigate the effect amino acid mutation has on the predicted 
potency of quinidine and quinine in all rat and human CYP2D models in these 
cases.
6.2 Sequence Analysis of Rat and Human CYP2D  
Enzymes
Using the simple prediction methodology applied earlier (see Chapter 5) it was 
possible to make a prediction of the most potent isomer in rat cytochrome P450s 
2D5 and 2D 18 for which no experimental binding information currently exists 
(see Chapter 5, Table 5.4). For all models based on 2F9Q and 3QM4, quinidine 
was predicted to be the more potent isomer in CYP2D5 and quinine in CYP2D18.
Using CLUSTALX and the MCE sequence alignment tool, a multiple sequence 
alignment was generated for all rat and human CYP2D enzymes before grouping 
the sequences based on their most potent isomer (Figure 6.1). Quinidine is shown 
to be the most potent isomer for rat CYP2D1, human CYP2D6 (see Chapter 1, 
Table 1.1 for experimental /C 50 values) and rat CYP2D5 (see chapter 5, Table 
5.4 for prediction) and quinine is the most potent isomer for rat CYPs 2D2, 2D3, 
2D4 (see Chapter 1, Table 1.1) and 2D 18 (see Chapter 5, Table 5.4).
117
6. Identification and Analysis of Residues Responsible for a Change
of Potency in Quinidine and Quinine
CYP2D€_EÜÎGK
CYP2D1_RS.T
CY?2D5_RS.T
CYP2D2_EAT
CY?2D3_RkT
CY?2E4_RS.T
GY? 2D 18 R?2r
HGLEA ^L\7?IAVr7MELIilT3IMEiRR-2RW?JiRYB F21JT PYC
MEm^GT sa,ifSM &iFTyiiYii\43iMEiRRP3iW T m Y D P a M ip m v iG m J ù V D i.sm P Y  S 
MEIJJ4GT5LWgM&IFI\a:YIM .\^ I « HRE‘2RgT SR Y P I ^ J B îÉVlaSHÎJiQTO ?SM ® Y  S
pM?r|sEiw? i>.m :i FiiiPmn mK. ;::«i s;.YP BGPVB;rp-.Y,GNu^ i#±^ b^ BAG
* * * * *
CY*?2D€_HDi-aN
CYP2D1_RJlT
CY?2D5_R3LT
CY?2D2_RAT
CYP2E3_RAT
CY?2D4_RJlT
GY?2D18 RAI
GY*?2D€_KDî-fiN
CY?2D1_E?.T
GYP2DS_RS.T
GY?2D2_RAT
GY?2D3_RAT
GY?2D4_RîlT
GY? 2D 18 RAT
m<aRmEBm%ïaLA*T#WÆKGia&vREAiiÿ%^  nGrceRso
LYKLQmY!aWISïaKG»KPî«fn'TOÏ£&lJQEmriEGEDTADR??;??IÏKGLG7KSiRSQ 
!'IïKI^ HRY’GDl’?SL34<^K?Mi"r>7îi!RiÆ3L\^ Er7TjVTK<SI3TADR??\??irEGLGl^ RSQ
:D? m JE L lY ltJK S K  
?IFaEI|Yt:KAK
F Y SEDTAmE? LE n ® ‘Q sl?§?R S Q
F Y SEDTAE ^ ?LKn'IDGS#F#?RSq
S7FIARYG?A5fRE’QRRFSVSTLKUÆLGSaœiÆ:<3BVrEEaÆGLCA2UrAlîHSGR?FRPlJGL 
OTHASYG?E5fREQRRFS\!^TLET itJiCSaCSIEEiryTKE&GHICl^JTAQAGQ SI1®KAM 
GVLrmSYG?EMREORRFSirSTLRT iG^O aE S IÆ E gyîKE&æiiCDAFTAatJGRSIIgEAM
fGPAMapïRFSVSIF|EiëlE^ IS<ïrVI$HRGfU:AJLFADHSGFflFsllîr| 
IFSVSTFgEpZlWcKSIJEOmniE^ RZg^ ETinESGFgFSgn:#
• ^  4  ^  ^  4i 4» -4
GY'?2D€_EDMAH
GY?2D1_RAT
GY?2D5_RAT
GY?2D2_RAT
GY?2D3_RAT
GY?2D4_RAT
GY? 2D IS RAT
u :  j :c c :  | 2 j ;  m  « :
IZlKAVSirL\IA5LTG3tRFEYDDeRFLRLLDLAGEGLEEESGFLREVLKAY?lT.LEI?ALA 
LHKALGKIT; A S II FARRFEYED FYLIIBRrKLVEESLTEl?SGFI?Eî?ÎJSrTFPALLRÎP GLA 
LIJîaiGKP.T;A.SLIFAREFEÏEDPYLIBMLTLVEESLI17JSGFI?KriJ!ÎTFPALLRI?GLA 
N E #E #F & n3#K T L K E S  FGËDTÊFMAEld
k::KAV::lWIAS] L s t y  FYï5mR#TRim DLLKDTLE#ES#FL?m|
CKBV :IMVI AS]|L - f G y  FY1T3 gRglRIgDLLKDTLE^SgFLA^ILl 
*  *  *  » * * * * * *  * * - *  *  *  — » • «  « - • *  • * » •  - *  *  *  * * - * *  *
GY?2D£_EDÏIAlî
GY?2D1_RAT
GY?2D5_RAT
GY?2D2_RAT
GY?2D3_RAT
GY?2D4_RAT
GY?2D18 RAT
GY'?2De_EDïIAN
GY?2D1_RAT
GY?2D5_RAT
GY?2D2_RAT
GY?2D3_RAT
GY?2D4_RAT
GY?2D1S_RAT
GY?2D£_EU>1AH
GY?2D1_RAT
GY?2D5_RAT
GY?2D2_RAT
GY?2D3_RAT
GY?2D4_RAT
GY?2DIS RAT
SKVIRLFQKAilTGUEILTEERMrSîD ?AQ??RDLTEAELAE'IEKaKGlT?ES SF1®EHTRI 
DKÂ^FQGQKT -^LALLntUiL AEHRTIWD ?AQ ??RN1T DAFLAEvrEKAKGM ?ES SF1ŒEI4LRM 
DRY^j GQKTSÏLATLDIttLAÆlJR'TTïfD ?AQ ??RHLT DAFLAEl\EEAK3; ?ES SFHDEHULM
3KVtSGOlJ\"AiniEIYT|ror..YSroEAÛPPRDYrEAEIiAr7EKAK(3JEESSFm:SHIff7 
[S 3CKA|A"AlIl|ELLTB .^Y^>i2P?RD 1TDAEIAE-7HKAKGNPES SFIÎDEMLRr.7 
• * * *  * * * * »  «* »*^*^*«^ * * * * * * * * * * * * *  * * * •
E-231 3 3 3 4
I I r.; 32: as: a<: aa: ai:
WADL FSA C H yn STTLANGLI.IMn.H?Dl^RR\^QE IDD VIGOVRRPntADQAEH? YTT 
W iTÎL FTAGHVrTATTlTHAlLI«IL Y?D\JQRR\?a'aE inEyi>3QWG?lKriX2AEM?YTH 
VvYTO, FTAfiH5nTAJTlTHAII.IMIL YADvfQRRl^'OE IDE’L'IQQyRGPEMTDQAJ-T’IAYTN
is*MKî*B«feEin$rtns5mi™am?EP?T^
^VIGQVRHPEMADQAHHP ^  
3 :  XœVTGQVRbJPEMADQ Ar JMP E #  
____________  :E  IDEVIGQVR;jPmADQ AFJM?
1?:  3j :  3: :  < : :  tiz u :
AJ7IEE\?QRFGD WPLGVTPTITSRD TEl^DGFRIPKS TT LITNL SS\T.KDEAVWEK? FRFE ? 
Aj;iKE\^RFGD LA?LNL?RFTS GD lE ’J^D rJ 'I?K 3T T L IIN L  SS\T.EDEn^rfEK?ERFH ? 
AVIEEv^RFGD IA?L1^L?RITS GD IE\!^D F.7I?KGTTLIIML SS\T,KDEmffiK? LRFH ? 
fcVIHEVQRFADMllJI^ lttSRDÎEF|P^ pKGiraB?ttSSVLKDETVWEKPLRFHS 
BTOiEVaRFADX; tn - Î I ^ : r S P I ) lE \ ;O T  USSVLKDETVWEKPLRFHB
BLG^jpSK r S R D l E i a t L m B S T m T  HLSSVLKDErVWEKPLRF^ 
g L S \# K  « R D Ï E \# Ë L p K G T T L ll  ttSSVLKDETVWEKPLREJi*
HnHEVaRFADjL
BTIHEVQRFArJlL
118
6. Identification and Analysis of Residues Responsible for a Change
of Potency in Quinidine and Quinine
CY?2D€_EUmJ
CY?2E1_RAT
CY?2D5_RAT
CYP2DZ_RAT
CY?£D3_RAT
CY?£E4_RAT
CYPZDIS RAT
a :  t s z  u :
EH iU3Ai2GKF\nQE&FL? FSAGSERATIÆE ?XAJt>lEIJXFS^SLLQE FS F S 7P I0Q  ?R?SH  
EHELDAaOîîVKEEAFMP FSAGRRACLGE?I.AR^IEI.FI,FFT=IÆORES FSsiW G Q  PRPS T 
EE FiZIAQGÎ'IFVKEEAFMP FSAGERACLGE ? 1  AR!-1EL?LFFTCLLQHFS5WPAQQ PRPST 
E][E]ZüèaaTFVKHEAEWKAGRRACIŒBIJmME]LFIfFTCiLLÜRË'y&'yËiJ
E3rEIJ3aQG3JFVmAgMPE5aGB!RACIÆEPIJaaEIJTJFTCLLQRESia^?T 
EXEmj^ GNFVKHEAFHPFSJ^ RRM;i£EPIJ^ ia4ElJXEETCLL<3RE^ lBI?T 
EHgLDAQQJgVKHE&FMP E5 AGRRACTLGE RL ARMELFLFFTCIJ.QRgS E5ai?A
PRSK3
ESSitT
* * * * * * * * * * * 4  * * * » * * * * * * * * * * * * * * * * ^ * * * * * * *  * - * * * *
CY?2Dc_HUmJ
CY?2D1_RAT
CY?2D5_RAT
CY?2E2_RAT
CY?2D3_RAT
CY?2D4_RAT
CYPZBia RAT
H3\i’EAFLVSPSFYEIiC?F/?REQ GL 
mFEAF?%n;FYÛLCAÂY7RE'ÛGE
LGKEAISIGlPLPÏ'OLCAAA^--------
KYAL?;T:|
Ky r fl is I 
ï J i f g a i t t |
ribFGALTTl ----
Figure 6.1: Multiple sequence alignment of all rat and human CYP2D enzymes 
grouped based on their most potent isomer. CYPs 2D1, 2D5 and 2D6 where 
quindine is the more potent isomer have areas of identity shown in light blue and 
CYPs 2D2, 2D3, 2D4 and 2D18 where quinine is the more potent isomer have 
areas of identity shown in dark blue. The residues shown in yellow are being 
investigated for the impact of stereochemistry on potency.
Analysis of this sequence alignment shows three amino acid residues, 209, 210 
and 388, that show identity in all rat CYPs 2D2, 2D3, 2D4 and 2D18 (Leu209, 
Lys210 and Leu388) where quinine is the more potent isomer but are not con­
served in CYPs 2D1, 2D5 and 2D6 where quinidine is more potent; residues 
Val209, Clu210 and Val388 in rat CYPs 2D1 and 2D5 and residues Ala209, 
Cln210 and Arg388 in human CYP2D6. These three residues (209, 210 and 
388) represent the only instances in the species alignment where areas of identity 
for one set of enzymes are not conserved in any way for the enzymes with an 
opposing potency. This indicates that these residues may be responsible in some 
way for the species selectivity observed for these chiral enantiomers, quinidine 
and quinine.
Residues 209 and 210 are within the active site on a-helix F near residue 216 
which is considered to be important for inhibitor binding and shows interactions 
with the majority of inhibitors in both rat and human CYP2D enzymes, sug-
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gesting that some change in this area will impact the inhibitor’s ability to form 
interactions. Residue 388 however appears on /3-sh.eet 2-2 (Figure 6.2) on the 
outside of the protein, away from the active site and as such is much harder to 
explain.
Figure 6.2: Positions of residues 209, 210 and 388 in relation to the active site of 
cytochrome P450 2D6.
6.3 Amino Acid M utation of Rat and Human 
CYP2D Enzymes
Using the sequence tool available in MOE [41], mutations were made to three 
amino acid residues in all existing rat and human CYP2D models (both the haem 
and compound 1 forms). Those residues present in rat CYPs 2D2, 2D3, 2D4 and 
2D 18 were mutated to be more favourable to quinidine by becoming more human 
(L209A, K210Q and L388R) and those residues in rat CYPs 2D1 and 2D5 and
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human CYP2D6 were mutated to increase favourability for quinine (V/A209L, 
E/V210K and V/R388L in rat CYP2D1/5 and human CYP2D6 respectively).
The mutations were performed both singly and in combination.
6.4 Virtual Screen of Quinidine and Quinine into 
the M utated Forms of Rat and Human CYP2D  
Enzymes
Quinidine and quinine were docked into all available structures of rat and human 
CYP2D enzymes using the available MOE [41] virtual screening program. The 
virtual screen was performed using a rigid-protein-rigid-ligand dock with a Lon­
don AG scoring function and no refinement step.
The angle of orientation was measured relative to the haem iron (see Chapter 
5, Figure 5.2) and recorded for all mid-point energy docks and their orientation 
assigned.
6.5 Effect of M utation on Predicted Potency of 
Quinine and Quinidine into Rat and Human 
CYP2D Enzymes
Based on the prediction methodology discussed earlier (see Chapter 5) the three 
residues Leu209, Lys210 and Leu388 in rat CYP2D were mutated to Ala212, 
Cln213 and Arg388 both singly and in combination and the placement of quini­
dine and quinine analysed.
6.5.1 Combined M utation of Residues 209, 210 and 388 
in Rat and Human GYP 2D Enzymes
For rat CYPs 2D2, 2D3, 2D4 and 2D18, residues Leu209, Lys210 and Leu388 
were mutated to Ala209, Cln210 and Arg388 and the placement of quinidine and
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quinine analysed using the decision criteria of the substrate/ inhibitor prediction 
methodology discussed previously (see Chapter 5). For all 2F9Q based structures, 
a change in the more potent ligand from quinine to quinidine was observed for rat 
CYPs 2D2 and 2D 18 and the compound 1 structure also showed an additional 
change for the remaining rat CYPs 2D3 and 2D4. The 3QM4 based structures 
showed a consistent change in the more potent ligand for rat CYP2D4 but while 
the haem form of these structures showed a change in the more potent ligand 
in the case of CYP2D2 and CYP2D18, the compound 1 form did not show this 
change and instead a change was observed for CYP2D3.
For rat and human CYPs 2D1, 2D5 and 2D6, residues 209, 210 and 388 were 
mutated to Leu209, Lys210 and Leu388. In this case, a consistent change in 
potency was seen for CYP2D6 in the 2F9Q based models, with the compound 1 
structure also showing a change for CYP2D1. For the 3QM4 based models, no 
consistent change in potency was observed, with rat CYP2D1 showing a change 
in potency for the haem structure and CYPs 2D5 and 2D6 showing the predicted 
change in the compound 1 structure.
Overall, a change in the more potent compound is observed on average 61% of 
the time for these mutations, however none of these mutations cause a consistent 
change in potency for all structures. Analysis of the position of these residues has 
already revealed residues 209 and 210 to be within the active site while residue 
388 is 29.09Â away from the haem iron in the 2F9Q structure and 28.62Â in 
3QM4. In order to first ascertain the importance of the mutation at residue 388, 
residues 209 and 210 will be mutated in combination and the results analysed.
6.5.1.1 A ctive Site M utation of R esidues 209 and 210 in R at and 
Human C Y P2D  Enzym es
The active site mutations in rat CYPs 2D2, 2D3, 2D4 and 2D18 again showed 
a consistent change in CYP2D2 and CYP2D18 for all 2F9Q based structures 
with a change in potency being predicted for the compound 1 forms of CYPs 
2D3 and 2D4. A change was again predicted for CYP2D2 in the 3QM4 based
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structures with CYPs 2D3 and 2D4 also being consistently observed. For the 
haem form of the 3QM4 based structures a change in potency is predicted for 
CYP2D18 but this is not observed for the compound 1 form. For the active 
site mutations of CYPs 2D1, 2D5 and 2D6 a consistent interaction was observed 
for human CYP2D6 for both the 2F9Q and 3QM4 crystal sturctures bar the 
native haem form of the 3QM4 based structure. The 2F9Q based structure also 
predicted a change in potency for CYP2D5 in the haem form and CYP2D1 for 
the compound 1 form. The 3QM4 based structures consistently show a predicted 
change in potency for CYP2D1 with the compound 1 form also showing a change 
in potency for CYP2D5. The overall precentage change in potency seems to 
increase in this case with 75% of CYPs showing a predicted change in potency 
on mutation of the active site residues. This seems to suggest that the mutation 
of residue 388 has little impact on the active site binding of chiral compounds, 
which is not unexpected given the position of this residue in relation to the active 
site. Single mutation studies have been carried out to investigate this m atter 
further.
6.5.2 Single M utations of Residues 209, 210 and 388
By mutating these residues individually and recording the predicted changes in 
potency for each case, there should be a clearer picture as to the importance of 
each residue to the species effect of a chiral compound.
6.5.2.1 M utation of the A ctive Site Residue 209 in Rat and Hum an  
C Y P2D
In rat CYPs 2D2-2D4 and 2D 18, Leu209 can be seen to point down into the ac­
tive site (Figure 6.3) with no obvious change in position or rot amer for either the 
2F9Q or 3QM4 based models. On mutation to Ala209 the conformation remains 
the same for both the 2F9Q and 3QM4 based structures and there is a significant 
loss of volume. Surface analysis shows the creation of a channel on mutation 
(Figure 6.4).
The docks of quinidine and quinine predicted a change in potency for CYP2D3
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Figure 6.3: The position of residue 209 in relation to the active site of the 2F9Q 
crystal structure based model of cytochrome P450 2D2.
Figure 6.4: Changes in the active site surface area on mutation of Leu209 (yellow) 
to alanine (blue) in the 2F9Q based model of rat CYP2D2.
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in all 3QM4 based models and the compound 1 form of the 2F9Q based model. 
The compound 1 3QM4 based model also showed a predicted change in potency 
for rat CYPs 2D2 and 2D4. No changes in potency were predicted for the haem 
only form of the 2F9Q based models for any cytochrome P450 2D enzymes.
For CYPs 2D1, 2D5 and 2D6, residue 209 was mutated to leucine. In this 
case, there is some observed variation in position from the combined and active 
site mutations performed previously. For the 2F9Q based model of rat CYP2D1 
a different rot amer of the mutated leucine residue is observed although this is not 
observed in the 3QM4 based model or either of the compound 1 forms (Figure 
6.5).
Figure 6.5: Variation in the rot amer ic form of the mutated leucine residue in the 
active site (grey) and single mutations (green) of the 2F9Q based model of rat 
CYP2D1.
As with rat CYP2D1, the single mutation of residue 209 in CYP2D5 shows a 
different rot amer ic form from that found in the combined models. In this case.
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the rot amer is observed for models based on both the 2F9Q and 3QM4 crys­
tal structures but again is not observed in either of the compound 1 forms. No 
changes in rot amer are observed for human CYP2D6. In this case, the mutation 
from valine (2D1 and 2D5) and alanine (2D6) to leucine causes an increase in the 
active site surface area due to the increase in residue size (Figure 6.6).
Figure 6.6: Changes in the active site surface area on mutation of Ala209 (yellow) 
to leucine (blue) in the 2F9Q crystal structure of human CYP2D6.
A predicted change in potency is observed for rat CYP2D5 in the 3QM4 and 
compound 1 form of the 2F9Q based model with CYP2D1 showing a change in 
potency for the compound 1 2F9Q and 3QM4 models. Again, no change in po­
tency is observed for models based on the haem only form of the 2F9Q crystal 
structure, nor are any changes in potency observed for human CYP2D6.
A change in the more potent ligand is observed only 32% of the time for the 
mutation of residue 209 in rat and human CYP2D enzymes, suggesting that this 
mutation has little impact on the overall effect of the active site and combined
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mutations. This is not unexpected given that these amino acid residues are 
fairly homologous. The only observable difference for those CYPs that show a 
change in potency is the variation in active site volume. For a change in the 
more potent ligand from quinine to quinidine a decrease in volume is observed 
while for a change to quinine as the more potent ligand an increase in volume 
is characteristic. This change in active site volume coupled with the position of 
this residue on helix F near substrate recognition site 2 (residues 213, 216 and 
217) [20] suggests that the change in potency is linked to a change in an access 
channel. The F and G helicies define a structural unit that covers the active site 
of cytochrome P450 enzymes, using the channel naming system set out by the 
Wade group [19] we can identify the impact that changes in this residue could 
have on both the solvent access channel and members of the channel 2 family 
(subchannels 2a, 2ac and 2c) formed in regions between the F-G loop and the 
B’-C loop or B’ helix (figure 6.7). Any changes in this region could have a direct 
impact on the enzyme binding of quinidine and quinine as these channels have 
been shown computationally and experimentally [98] to open and even merge to 
allow the access and egress of molecules the size of substrates and products.
6.5.2.2 M utation of the A ctive Site Residue 210 in R at and Human  
C Y P2D
In all forms of rat CYPs 2D2-2D4 and 2D 18, Lys210 can be seen to face away 
from the central haem binding site due to its position on o-helix F (Figure 6.8). 
On mutation of Lys210 to glutamine the conformation remains the same for both 
the 2F9Q and 3QM4 structures with some loss in volume and a change in charge 
from positive to neutral (Figure 6.9).
A consistent change in potency is observed for all 2F9Q and 3QM4 based 
models of CYPs 2D3 and 2D4. CYP2D2 shows an observed change in potency 
from quinine to quinidine on mutation to glutamine in models based on 3QM4 
and the compound 1 form of the 2F9Q model, while both compound 1 2F9Q and 
3QM4 models show a predicted change in potency for rat CYP2D18 and as such 
show a change for all rat CYPs with quinine as the more potent ligand.
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Figure 6.7: Effect mutation at residue 209 may have on the channel 2 family in 
the 2F9Q crystal structure of human CYP2D6. The F-G loop is shown in blue 
and the B’ helix in yellow.
Figure 6.8: Position of residue 210 in relation to the active site of the 2F9Q 
crystal structure based model of cytochrome P450 2D2.
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Figure 6.9: Change in charge and active site surface area on mutation of Lys210 
to glutamine in the 2F9Q based model of rat CYP2D2. Areas of negative charge 
are shown in red, neutral regions are in white and areas of positive charge are 
shown in blue.
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For CYPs 2D1, 2D5 and 2D6 the mutation of residue 210 to lysine, in the 
majority of cases, shows no variation in orientation or position from the combined 
and active site mutations with the exception of the 2F9Q structure of CYP2D6 
which shows the mutated lysine to be in a different rotameric form (Figure 6.10). 
This change is not observed in the 3QM4 based model or either of the compound 
1 forms.
Again a change in charge is observed on mutation with a change to positive 
from neutral for the mutation of glutamine to lysine in human CYP2D6 and in 
the case of rat CYPs 2D1 and 2D5 a change from the negative charge of glutamic 
acid to a positive charge with lysine (Figure 6.11).
CYP2D5 is consistently predicted to show a change in potency from quinidine 
to quinine in all 2F9Q and 3QM4 based models. For the compound 1 forms of 
both 2F9Q and 3QM4 based models a change in potency is predicted for rat 
CYP2D1. Human CYP2D6 also shows a change in potency but in this case only 
for the 3QM4 based structures and not the 2F9Q models. Closer analysis of the 
mutations in these structures show the 3QM4 based models to have a different 
rotameric form of lysine from that found in the 2F9Q models suggesting that the 
position and orientation observed at residue 210 has an impact on the placement 
and approach of a docked compound to the active site. In fact further inves­
tigation shows that the placement of Lys210 in the mutated 2F9Q structure of 
human CYP2D6 moves the positive charge away from the active site preventing 
the change in charge from interferring with the quinidine dock (Figure 6.12).
Overall, a predicted change in potency is observed 75% of the time suggesting 
that the change at residue 210 is the main contributing factor to the effect of 
the active site mutations. Again, given the more dramatic change in charge it is 
not unexpected that this residue would have more of an effect on the predicted 
potency and therefore the species selectivity of isomers quinidine and quinine.
Further investgation reveals, not unexpectedly, that the presence of a neg-
130
6. Identification and Analysis of Residues Responsible for a Change
of Potency in Quinidine and Quinine
/
Figure 6.10: Variation in the rotameric form of the mutated lysine residue in the 
active site (grey) and single mutations (green) of the 2F9Q crystal structure of 
human CYP2D6.
Figure 6.11: Change in charge and active site surface area on mutation of Ghi210 
to lysine in the 2F9Q based model of rat CYP2D1. Areas of negative charge are 
shown in red, neutral regions are in white and areas of positive charge are shown 
in blue.
131
6. Identification and Analysis of Residues Responsible for a Change
of Potency in Quinidine and Quinine
Figure 6.12: V ariation in the  rotam eric form of the  m u tated  lysine residue in the  
3QM4 (grey) and the  2F9Q (green) crystal s tructu re  of hum an CYP2D6.
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ative charge at residue 210 results in quinidine as the more potent ligand and 
a positive charge at residue 210 is characteristic of quinine as the more potent 
ligand. Again, this change in active site occurs on helix F near substrate recog­
nition site 2 [20]. In this case, the change in ligand appears to more directly 
effect the solvent access channel given its position between the E, F and I helices 
[19, 98]. Changes in the channel 2 family (in this case subchannels 2ac and 2c) 
are still possible which again may have a direct impact on the enzyme binding 
of quinidine and quinine (Figure 6.13). This follows for the combined and active 
site residues with this observed change in charge in combination with the change 
in active site volume on mutation of residue 209 appearing to farily accurately 
predict the more potent ligand.
Figure 6.13: Effect a mutation at residue 210 may have on the channel 2 family 
in the 2F9Q crystal structure of human CYP2D6. The F-G loop is shown in blue 
and the B’ helix in yellow.
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6.5.2.3 M utation of Residue 388 in Rat and Human C Y P2D
Mutation of LeuSSS to arginine in rat CYPs 2D2, 2D3, 2D4 and 2D 18 does not 
show any one cytochrome P450 enzyme to have a consistently observed change in 
predicted potency. For all 2F9Q based models CYPs 2D2, 2D3 and 2D 18 are pre­
dicted to change the more potent ligand, with the compound 1 form also showing 
rat CYP2D4 to have a change in potency. For the 3QM4 based models CYP2D4 
shows a change in potency in both cases with CYPs 2D2 and 2D 18 showing a 
predicted change in potency for the haem form and CYP2D3 showing a change 
in potency for the compound 1 form. No changes in orientation or position were 
observed from the combined mutations.
For the mutation of CYPs 2D1, 2D5 and 2D6, a consistently predicted change 
in potency is observed for rat CYPs 2D5 and 2D6 for all 2F9Q based models 
and the compound 1 form of the 3QM4 based models. No predicted changes in 
potency are observed for the haem forms of the 3QM4 based structures. The 
compound 1 forms of both models also show a predicted change in potency for 
CYP2D1.
Overall a predicted change in potency is observed for 68% of the docks per­
formed suggesting that this residue has quite an impact on the cytochrome P450 
active site. Given the position of this residue (%29Â from the haem iron) it is 
difficult at first to identify how it has this level of impact. In the majority of cases 
there is no variation in the position or orientation of the residue mutations with 
the exception of the 3QM4 based model of CYP2D1 suggesting that the position 
is not an impacting factor.
Previous work by Lewis [98], investigated the long-range effects of a mutation 
at F186 in a genetic variant of CYP1A2 which strongly effects enzymatic activity 
despite being 27.76Â from the haem iron (Figure 6.14). In this case, the muta­
tion was found to cause an increase in the structural flexibility without changing 
the overall structural fold of the enzymes. An observed motion around helicies 
D, E and F near the main molecular access channel (the solvent access channel
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and the channel 2 subfamily) showed the F186L mutant protein to exist in two 
subpopulations of conformational states, corresponding to the open or closed con­
formation of the substrate access channel.
Figure 6.14: Position of F186 relative to the haem group in the crystal structure 
of human CYP1A2 (pdb code: 2HI4) [98].
Using LowMode MD and the MOE conformational search program, a series 
of flexibility studies have been performed to investigate whether the peripheral 
mutation at residue 388 has any long range effects on the active site of human 
CYP2D6. This single mutation is shown to change the more potent compound 
in all cases of CYP2D6 bar the haem form of the 3QM4 crystal structure and so 
provides a good starting point for these preliminary investigations.
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6.5.3 A ctive Site Flexibility and its Effect on Species Se­
lectivity
Using the MOE conformational search program [41], LowMode MD [63] was used 
to investigate any possible increase in flexibility for the R388L mutant of human 
CYP2D6. Ten thousand iterations were performed with a root mean squared 
deviation limit of 0.25Â from the starting structure. The conformational search 
was performed for all haem and compound 1 forms of both the 2F9Q and 3QM4 
crystal structures in vacuo and in solvent (a water box). Both the haem and 
residue 388 were held rigid throughout the conformational search.
For the 2F9Q crystal structure of human CYP2D6 Arg388 can be seen on p- 
sheet 2-2 showing hydrogen bonding interactions with the surrounding residues 
Pro390, Ile389, Phe387, Ile382 and Pro34. On mutation to Leu388 the ^5-sheet 
secondary structure is retained and hydrogen bonding interactions are observed 
with Pro390, Ile389, Ile382 and Pro34. The conformational search was then per­
formed for the mutated haem form of CYP2D6 in vacuo. In this case, eight 
possible conformations were identified, all showing some loss of secondary struc­
ture with an average RMSD (Ccr) of 3.24Â and 2.17Â for the active site alone 
(Figure 6.15).
Overall, there is little variation in these conformations, with the majority of 
the structures showing the loss of a-helix K” and /3-sheets 3-3, 4-1 and 4-2 as 
well as some minor shortening and extension of helicies throughout the structure. 
Interactions are observed with Pro390, Ile398, Phe387, Ile382, Glu383 and Pro35. 
As expected, when performed in solvent the amount of structural variation de­
creases dramatically with little loss of secondary structure (only ^-sheets 4-1 and 
4-2 near the C-terminus) and an average RMSD (Ca) of 1.03Â and 0.71Â for the 
active site (figure 6.16). However, in this case the movement of the surroundings is 
such that interactions can only be observed with Phe387 and Ile389 (Figure 6.17).
The compound 1 forms of the mutant structures show more significant protein 
flexibility with the conformational search performed in vacuo showing an almost
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Figure 6.15: Conformation of the mutated haem form of the 2F9Q human 
CYP2D6 crystal structure in vacuo.
Figure 6.16: Conformation of the mutated haem form of the 2F9Q human
CYP2D6 crystal structure in solvent.
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Figure 6.17: Movement of the residues surrounding R388L in the conformational 
search of the haem form of the 2F9Q crystal structure in vacuo. The residues in 
green show the movement of the mutated structure while those in grey show the 
original crystal structure. Arg388 of the crystal structure is shown in pink.
complete loss of structure with only a small number of helix turns remaining 
of helicies A, J, J ’ and L and an RMSD (Co) of 10.23Â for the whole protein 
and 9.19Â for the active site alone (Figure 6.18). As in the crystal structure, 
interactions are observed with Phe387, Ile382 and P34 with an additional inter­
action being observed with Gly386. Due to the unusual nature of this result, the 
conformational search was repeated. Again, an almost complete loss of structure 
was observed, suggesting either an unexpected level of flexibility in this case or a 
systematic error in MOE.
In a water box this flexibility is constrained but greater flexibility is observed 
than that of the haem structure with an RMSD (CA) of 1.61Â (which increases 
to 1.75Â in the active site) and the loss of secondary structure at helix K” and 
/3-sheets 1-1, 1-4, 4-1 and 4-2 (Figure 6.19). In this case, interactions are observed
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Figure 6.18: Conformation of the mutated compound 1 form of the 2F9Q human 
CYP2D6 crystal structure in vacuo.
H M s .
%
Figure 6.19: Conformation of the mutated compound 1 form of the 2F9Q human 
CYP2D6 crystal structure in solvent.
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at Pro390, Ile398, Phe387 and Ile382.
For the 3QM4 crystal structure of human CYP2D6, Arg388 shows hydro­
gen bonding interactions with the Pro390, Ile389, Phe387, Ile382, Asp381, Pro34 
and Leu33. On mutation to Leu388, the /5-sheet secondary structure is retained 
and all but the interaction with Asp381 remains possible. The conformational 
search was then performed for the mutated haem form of CYP2D6 in vacuo. 
In this case only one possible conformation was identified showing some loss of 
secondary structure (loss of helices F ’, K” and /5-sheets 1-4, 4-1 and 4-2) and a 
smaller RMSD (CA) of 2.16Â (1.71Â in the active site) than that observed for the 
2F9Q models (Figure 6.20). As in the crystal structure, interactions are observed 
with residues Pro390, Ile389, Phe387, Ile382, Glu383 and Leu33.
Figure 6.20: Conformation of the mutated haem form of the 3QM4 human 
CYP2D6 crystal structure in vacuo.
Under solvent this flexibility is constrained with an RMSD (Cq ) of only 0.66Â 
(and only 0.63Â in the active site) and some minor changes in the secondary
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structure (Figure 6.21). In this case, interactions are observed at Pro390, Ile398, 
Phe387, Jle382, Pro34 and Leu33.
ÎÏ3&
Figure 6.21: Conformation of the mutated haem form of the 3QM4 human 
CYP2D6 crystal structure in solvent.
Again, the compound 1 forms of the mutant structures show more protein 
flexibility, however in this case not to the extent observed previously. For the 
conformational search performed in vacuo an RMSD (CA) of 2.39Â (and 2.04Â 
in the active site) was observed from the crystal structure with some change 
in secondary structure and loss of structure at helix B’ and /5-sheets 2-1 and 4-1 
(Figure 6.22). Interactions are also observed with Pro390, Ile389, Phe387, Glu383 
and Ile382.
Under solvent an RMSD (CA) of 1.88Â (1.83Â in the active site) is observed 
along with some minor changes in the secondary structure and loss of structure 
at helices F ’, B’ and /5-sheet 4-2 (figure 6.23). Interactions are once again ob­
served at Pro390, Ile398, Phe387, Ile382, Pro34 and Leu33. Unfortunately, it has
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J
Figure 6.22: Conformation of the mutated compound 1 form of the 3QM4 human 
CYP2D6 crystal structure in vacuo.
l i
A
J2.
Figure 6.23: Conformation of the mutated compound 1 form of the 2F9Q human 
CYP2D6 crystal structure in solvent.
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not been possible to identify any specific interaction which could have caused the 
change in potency for all cases bar the haem form of the 3QM4 crystal structure 
of CYP2D6.
The paper from Lewis et. al [98] describes two possible and not mutually 
exclusive mechanisms to explain the long range effects of the peripheral F186L 
mutation on substrate binding; a size mechanism and an access mechanism. In 
the size mechanism, the mutation causes a reduction in the size and shape of the 
protein’s active site that significantly reduces the chances of substrate binding, 
while the access mechanism suggests that binding becomes less favourable due 
to the closure of the access channels on mutation. Given the movement observed 
during the conformational analysis, it is possible that the mutation R388L of 
human CYP2D6 is having an impact on either the access or size of the binding 
site which impacts on the ability of one isomer binding over the other. While 
more extensive dynamics research would be required in order to make any sort of 
definitive statement on this subject, some preliminary investigation into the size 
and access channels of these conformations has been conducted.
Using the active site dimensions set out by Lewis et. al [98] (Table 6.1), we 
can see that on mutation of P hel86 in GYP1A2 there is an overall decrease in 
size especially a decrease in the active site length (%^1.6Â decrease on average 
when compared to the wild type).
Dimension Definition 2HI4 Wild Type F186L mutant
length
width
height
N312 - Ga - L497 - Ga 
S122 - GcK - G316 - Ga
1117 - Ca - Haem Fe
16.8
10.5
16.4
17.6 ±  0.3
10.1 ±  0.3
16.1 ±  0.4
16.0 ±  0.3
10.0 ±  0.3 
15.8 ±  0.4
Table 6.1: Active site dimensions (in Â) of the wild type and the F186L mutant 
structures of CYP1A2.
In the case of the Arg388 mutation in GYP2D6, the active site structure 
changes are much less clear cut with only a reduction in the active site width 
being consistently observed, with the exception of the compound 1 mutant con­
formation of the 2F9Q crystal structure in vaeuo, however this is not unexpected
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given the almost complete loss of secondary structure in this case (Table 6.2). 
Overall, there is an average reduction in active site width of %0.85Â for the 
models based on 2F9Q (excluding the compound 1 in vacuo structure) which 
increases to pyl.74Â for the 3QM4 mutants. Changes in the active site length are 
observed in this case with the 2F9Q haem mutants showing an average increase 
of %0.64Â and the 2F9Q compound 1 mutants showing a decrease of %1.53Â 
(excluding the in vacuo structure). This reverses for models based on the 3QM4 
crystal structure which show a decrease in active site length for the haem forms, 
an average of %i2.15Â, and an increase for the compound 1 forms, an average of 
%1.51Â. In the majority of cases the active site height appears to increase slightly.
For those cases that show a change in the more potent enzyme to quinine 
from quinidine the active site dimensions show an overall increase in active site 
length with the exception of the mutant compound 1 form of the 2F9Q crystal 
structure which is not observed for those mutants where quinidine remains the 
more potent enzyme.
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Lewis et. al [98] also investigated the impact these slight changes in the active 
site dimensions had on the active site volume showing a decrease of almost half 
that of the wild type (Table 6.3).
Snapshot (ns) Wild Type 2HI4
11 186 78
12 157 116
13 176 68
14 118 122
15 197 39
16 126 73
17 170 109
18 199 124
19 157 79
20 190 85
Average 170 ±  30 90 ±  30
Table 6.3: Solvent accessible volume of the active site (in Â^) for the wild type 
and the F186L mutant of CYP1A2 estimated by Pocket [99].
In the case of the Arg388 mutation an increase in the active site volume is 
observed with the exception of the haem form of the 2F9Q crystal structure in 
vacuo (Table 6.4). An increase in volume is also observed for quinine as the more 
potent ligand during the mutation of Leu209 suggesting that active site size does 
have an impact on the preferred isomer. This along with the location of Leu209 
on helix F in the region of the access channel 2 subfamily and the consistent 
reduction in helix length observed during the conformational search at the F, 
G and H helices suggest that the structural flexibility also has an effect on the 
access channels available for molecules to enter the active site. Further dynamics 
research is requried to investigate this m atter fully, the details of which will be 
discussed in the Future Work (Chapter 8).
6.6 Conclusion
The results shown here suggest a link between residues 209, 210 and 388 and the 
species selectivity of rat and human CYP2D enzymes for the isomers quinidine
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Protein Structure Volume /
Human CYP2D6 (2F9Q) 7013
2F9Q R388L Mutant in vacuo* 7130
2F9Q R388L Mutant in solvent 6862
2F9Q Compound 1 R388L Mutant in vacuo 7549
2F9Q Compound 1 R388L Mutant in solvent 7104
Human CYP2D6 (3QM4) 7091
3QM4 R388L Mutant in vacuo 7108
3QM4 R388L Mutant in solvent 7233
3QM4 Compound 1 R388L Mutant in vacuo 7332
3QM4 Compound 1 R388L Mutant in solvent 7467
Table 6.4: Active site volume (in Â^) of the haem and compound 1 forms of the 
mutated 2F9Q and 3QM4 crystal structures of human CYP2D6 estimated by 3V 
[43]. * Average volume of all conformations found.
and quinine. These residues seem to have an impact not only on the size of 
the active site but also on molecular access. Residues 209 and 210 are found 
within the active site near substrate recognition site 2 well within the path of the 
solvent access channel and the predicted channel 2 family. Residue 388, however, 
is located far from the active site but as previous work from this group has shown 
in the case of the CYP1A2, the preliminary results here suggest a smaller active 
site and reduced access in rat CYPs 2D1 and 2D5 and human CYP2D6 as being 
responsible for the higher inhibitory potency of quinidine.
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Conclusion
Three novel amino acid residues have been identified which are predicted to im­
pact the species selectivity of chiral enantiomers as observed for quinidine and 
quinine in the rat and human CYP2D enzyme family. 3D homology models of 
the six rat CYP2D enzymes have been constructed based on both the available 
human CYP2D6 crystal structures (2F9Q [8] and 3QM4 [9]) to investigate the 
interactions observed between the isomers quinidine and quinine. Models were 
constructed under the CHARMM27 force field in order to minimise the obstacle 
posed to conventional molecular mechanics techniques by the haem iron.
Molecular docking studies were performed for quinidine and quinine into both 
the haem only and compound 1 forms of the rat and human CYP2D family. These 
studies suggest that there is no one amino acid residue interaction that could be 
determined to be responsible for the variation in inhibition observed between 
species but rather a change in the number of non-specific binding interactions 
occuring. This hypothesis was then extended to a further six inhibitors which 
showed similar responses. Work from MacCallum et al. [78] on molecular recog­
nition in antibody:antigen interactions shows a similar mechanism for antibody 
recognition of a wide variety of ligands.
Further docking studies were performed using a series of well known substrates 
to investigate the behaviour of both substrates and inhibitors. Surface analysis 
showed a distinct difference in the overall placement of substrates and inhibitors
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in the active site relative to the haem iron. In the majority of cases, for models 
based on both the 2F9Q and 3QM4 structures, inhibitors were found to dock par­
allel to the haem group, lying across the active site and effectively blocking access 
to the haem, while substrates were found to dock normal to the haem group, mov­
ing down through the centre of the active site. Using this information a simple 
prediction methodology was created to identify substrates and inhibitors in early 
stage drug discovery. In a virtual screen of these compounds into both the haem 
and compound 1 forms of rat and human CYP2D enzyme models an average 
overall agreement with hypothesis of 66% and 58% was found for models based 
on the 2F9Q and 3QM4 crystal structures respectively. Substrates were correctly 
predicted 42% and 38% of the time for 2F9Q and 3QM4 based models which 
is comparable to the results received through conventional scoring mechanisms, 
e.g. a previous docking study from Vermeulen et al. [100] showed hit rates and 
yields of only 12% and 30% rep actively for the FlexX-Dock docking-scoring pair, 
4% and 10% for GOLD-Goldscore and 24% and 60% for the GOLD-Ghemscore 
combination. ANOVA variance analysis also showed promise predicting P-values 
of 0.22 and 0.10 for docking into the haem 2F9Q and compound 1 3QM4 models 
respectively. Further refinement is however required before this technique could 
be relied upon to correctly predict the action of a drug in the cytochrome P450 
2D enzyme family.
Using this prediction method the more potent isomer from either quinidine or 
quinine was identified for rat cytochrome P450 enzymes 2D5 and 2D 18. Sequence 
analysis was used to identify three amino acid residues, 209, 210 and 388, that 
show identity in all rat GYPs 2D2, 2D3, 2D4 and 2D18 (Leu209, Lys210 and 
Leu388) where quinine is the more potent isomer but are not conserved in GYPs 
2D1, 2D5 and 2D6 where quinidine is more potent; Val/Ala209, Glu/Gln210 and 
Val/Arg388 in rat GYPs 2D1 and 2D5 and human GYP2D6 respectively. These 
three residues represent the only instances in the species alignment where areas 
of identity for one set of enzymes are not conserved in any way for the enzymes 
with an opposing potency, indicating that these residues may be responsible in 
some way for the species selectivity observed for these chiral enantiomers, quini­
dine and quinine. These residues were mutated (both singly and in combination)
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and molecular docking performed to show a reversal in the more potent isomer. 
Residue 210 was found to have the greatest effect on species selectivity with 75% 
of models showing a reversal. Residues 209 and 210 are both located in the ac­
tive site on a-helix F near substrate recognition site 2 and within the vicinity of 
the channel 2 family of access channels, specifically subchannels 2a, 2ac and 2c 
[19, 98]. Residue 388 is on yd-sheet 2-2 approximately 29Â from the haem iron and 
while not directly within the path of an access channel the preliminary flexibility 
studies show that mutation at this residue could have an impact on both the size 
of the active site and the availability of access channels.
Given the importance of the cytochrome P450 2D enzyme family to drug 
metabolism, being reponsible for the metabolism of %20% of therapeutic drugs 
in current clinical use, the observed species selectivity of the isomers, quinidine 
and quinine, in the GYP2D family poses a serious challenge to the identification 
of new chemical entities by the pharmaceutical industry. New homology models 
of rat GYPs 2D1- 2D5 and 2D 18 have been produced based on both the avail­
able 2F9Q and 3QM4 cytochrome P450 2D6 crystal structure, molecular docking 
has been performed to investigate the amino acid interactions with a series of 
well known GYP2D6 substrates and inhibitors indicating a binding mechanism 
based on molecular recognition similar to that shown in antibody:antigen inter­
actions. A simple descriptor has been created for the early stage identification of 
substrates and inhibitors based on the orientation of a compound when docked 
in the active site, which, while not currently fully predictive does show early 
promise. Predictions have been made as to the more potent isomer of quinidine 
and quinine in rat GYPs 2D5 and 2D 18 for which no experimental binding in­
formation is currently available and three novel residues identified from sequence 
analysis which are proposed to change the more potent diastereomer in a series of 
computational mutation studies providing a new avenue for investigation which 
potentially could contribute not only to pharmaceutical research but also that of 
the wider scientific community.
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Future Work
There is a great deal of future work to be done within this area including both 
new research and refinements to the preliminary work described here.
The rat CYP2D homology models can be improved through the use of a molec­
ular mechanics force field parametersied for use with transition metals, such as 
LFMM as applied in the DommiMOE application from the Deeth group [72]. 
More accurate representation of the haem group within the active site could help 
to improve the docking results achieved. These docking studies could also be 
improved through the use of an alternative docking and scoring program, such as 
GOLD-Chemscore, which was found in a work by de Graaf et al. [100] to be the 
most effective docking and scoring combination for the prediction of high-affinity 
GYP 2D 6 substrates. Given the difficulties encountered by MOE in docking aro­
matic compounds such as those common to GYP2D enzymes it is likely that an 
alternative docking program would also make a fiexible-ligand-rigid-protein dock 
possible rather than the rigid-ligand-rigid-protein dock performed here. This 
work [100] also suggested that the addition of active site waters could be benefi­
cial to the virtual screening of substrates and, as such, any further docking and 
virtual screen should be performed in both instances.
In the case of the prediction methodology presented here (see chapter 5) not 
only would these changes to the docking methodology improve results but an ex­
tension of this method to all the virtual screen docking poses received would help
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give a clearer idea of the docking topology for each compound. This prediction 
would also be improved with the creation of a series of rules defining substrates 
and inhibitors by taking into account not only the angle relative to the haem iron 
but also the overall directionality of the docked compound. These rules could 
then be incorporated into a set of molecular descriptors for ease of screening.
For the three novel amino acid residues identified, a series of energy degener­
ation studies should first be performed, which if successful could be followed by 
a series of single and combined site directed mutagenesis and competitive inhi­
bition studies to experimentally show what, if any, effect these residues have on 
species selectivity for isomers. Computational methods such as molecular dynam­
ics (>lns) and principal component analysis [101, 102] could be used to investi­
gate the impact of these residues on the global protein motion while CARVER 
[103] can be used to identify any changes to the access channels from the protein 
surface to the active site.
The work performed within this thesis provides a preliminary investigation 
into the possible mechanism affecting species selectivity in the cytochrome P450 
2D enzyme family and the future work detailed here could provide a clearer 
picture of this phenomenum.
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A ppendix A: Interaction Analysis 
of Quinidine and Quinine in Rat 
and Human Cytochrom e P450  
2D Enzymes
A .l Ligand-Protein Interaction Diagrams
Due to the complexity of the interaction tables discussed in chapter 4, a series of 
figures showing this information pictorially has been produced.
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A. 1.1 Ligand Interaction with Cytochrome P450 2D1
A. 1.1.1 Rigid-Ligand-Rigid-Protein Docks into the N ative Haem  Form  
of CY P2D 1
Figure 1: In teraction  diagram  showing the  rigid-Iigand-rigid-protein dock of th e  
quinidine crystal s tructu re  into the  2F9Q based model of CYP2D1. P red icted  
interactions are shown in blue.
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Figure 2: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of the  
quinidine molecular s tructu re  into the  2F9Q based model of CYP2D1. P redicted  
interactions are shown in blue.
Figure 3: Interaction diagram showing the rigid-ligand-rigid-protein dock of qui­
nine into the 2F9Q based model of CYP2D1. Predicted interactions are shown
in blue.
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Figure 4: In teraction  diagram  showing the  rigid-ligand-rigid-protein dock of the 
quinidine crystal s truc tu re  into the  3QM4 based model of CYP2D1. P redicted  
hydrogen bonding interactions are shown in blue and tt in teractions w ith a dashed 
yellow line.
Figure 5: Interaction diagram showing the rigid-ligand-rigid-protein dock of the
quinidine molecular structure into the 3QM4 based model of CYP2D1. Predicted
interactions are shown in blue.
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rFigure 6; In teraction diagram  showing the  rigid-ligand-rigid-protein dock of qui­
nine into the  3QM4 based model of CYP2D1. P redicted  interactions are shown 
in blue.
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A .1.1.2 Induced Fit Docks into the Native Haem Form of CYP2D1
Thr309
Figure 7; In teraction  diagram  showing the  induced fit dock of the quinidine 
crystal s tructu re  into the  2F9Q based model of CYP2D1. P redicted  in teractions 
are shown in blue.
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Figure 8: In teraction diagram  showing the  induced fit dock of the  quinidine 
molecular structu re  into the  2F9Q based model of CYP2D1. P redicted  hydrogen 
bonding interactions are shown in blue and tt interactions w ith a dashed yellow 
line.
Figure 9: Interaction diagram showing the induced fit dock of quinine into the
2F9Q based model of CYP2D1. Predicted interactions are shown in blue.
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Figure 10: In teraction  diagram  showing the  induced fit dock of the  quinidine 
crystal s tructu re  into th e  3QM4 based model of CYP2D1. P redicted  hydrogen 
bonding interactions are shown in blue and tt interactions w ith a dashed yellow 
line.
Figure 11: Interaction diagram showing the induced fit dock of the quinidine
molecular structure into the 3QM4 based model of CYP2D1. Predicted interac­
tions are shown in blue.
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Figure 12: In teraction diagram  showing th e  induced fit dock of quinine into the  
3QM4 based model of CYP2D1. P redicted  interactions are shown in blue.
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A. 1.1.3 Rigid-Ligand-Rigid-Protein Docks into the Compound 1 Form
of CYP2D1
f
r i
Figure 13: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of the  
quinidine crystal s truc tu re  into the  com pound 1 form of the  2F9Q based model 
of CYP2D1. P redicted  interactions are shown in blue.
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Figure 14: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of the 
quinidine molecular s tructu re  into the  com pound 1 form of the  2F9Q based model 
of CYP2D1. P redicted interactions are shown in blue.
Figure 15: Interaction diagram showing the rigid-ligand-rigid-protein dock of qni-
nine into the compound 1 form of the 2F9Q based model of CYP2DI. Predicted
interactions are shown in blue.
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JFigure 16: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of the  
quinidine crystal s tructu re  into the  com pound 1 form of the  3QM4 based model 
of CYP2D1. P redicted interactions are shown in blue.
Figure 17: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of the  
quinidine molecular s tructu re  into the com pound 1 form of the  3QM4 based m odel 
of CYP2D1. P redicted  interactions are shown in blue.
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Figure 18: In teraction diagram  showing the  rigid-ligand-rigid-protein dock of qui­
nine into the  com pound 1 form of the  3QM4 based model of CYP2D1. Predicted  
interactions are shown in blue.
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A .1.1.4 Induced Fit Docks into the Compound 1 Form of CYP2D1
Figure 19: In teraction diagram  showing the  induced fit dock of th e  quinidine 
crystal s truc tu re  into the  com pound 1 form of the  2F9Q based model of CYP2D1. 
P redicted  interactions are shown in blue.
1 8 0
Figure 20; In teraction diagram  showing the  induced fit dock of the  quinidine 
molecular s tructu re  into the  com pound 1 form of the  2F9Q based model of 
CYP2D1. P redicted  hydrogen bonding interactions are shown in blue and tt 
interactions w ith a dashed yellow line.
Figure 21: In teraction diagram  showing th e  induced fit dock of quinine into the  
com pound 1 form of the  2F9Q based model of CYP2D1. P redicted  hydrogen 
bonding interactions are shown in blue and tt interactions w ith a  dashed yellow 
line. 181
Figure 22: In teraction  diagram  showing the  induced fit dock of th e  quinidine 
crystal s tructu re  into the  com pound 1 form of the  3QM4 based model of CYP2D1. 
Predicted interactions are shown in blue.
Figure 23: Interaction diagram showing the induced fit dock of the quinidine
molecular structure into the compound 1 form of the 3QM4 based model of
CYP2D1. Predicted interactions are shown in blue.
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Figure 24: In teraction  diagram  showing the  induced fit dock of quinine into the 
com pound 1 form of the  3QM4 based model of CYP2D1. P redicted  interactions 
are shown in blue.
Interaction diagrams for the remaining rat and human cytochrom e 
P450 2D enzym es are available on request.
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A ppendix B: M odelling Species 
Selectivity in Rat and Human  
Cytochrom e P450 2D Enzym es
M odelling Species Selectivity in R at and Hum an Cytochrom e P450 2D  
Enzym es, Grace. H. C. Edmund, David F. V. Lewis, Brendam J. Howlin Plos 
One , Volume 8, Issue 5, I4 May 2013, e6SSS5
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Introduction
Human cytochrome P450 2D6 (CYP2D6), part of the 
cytochrome P450 (CYP450) superfamily of heme containing 
enzymes, plays an important role in the phase I mono-oxygenase 
metabolism of xenobiotic substrates being responsible for the 
metabolism of —20% of therapeutic drugs in current clinical use 
[ 1 ]-
R-H +  O2 +  N A D PH  +  H + -^ R -0 H  +  H 2 0  +  N A D P  “ ( 1)
The importance of CYP45ÜS to drug metabolism has long made 
them a target for investigation e.g. oxidation by CYP450s can 
activate prodrugs to their therapeutically active form, while their 
wide substrate specificity' can result in drug-drug interactions, often 
detrimental to patient health. This is particularly obvious in the 
case o f the CYP2D family, which due to its highly pol)'morphic 
nature can have a great deal of variability in terms of its 
metabolism. Better understanding of the molecular determinants 
of reactiv'ity and specificity is therefore required.
Traditionally, animal models are used to predict a drug’s 
ADM E-Tox properties, with the rat being one of the most 
common animal models used. Howev'er, there are questions 
regarding the transferability of these models to Human. Rats, after 
all, have 6 CYP2D enz^'mes; CYP2D1-2D5 and CYP2D18, 
compared to only one in humans, CYP2D6. The rat and human 
CYP2D isoforms show a reasonably high sequence identity overall 
(=56%) but this is significantly lower in the active site region 
(=34%).
A key example o f this is the observed species difference is the 
effect of chirality on CYP2D6. The chiral enantiomers of
quinidine and quinine show a species selective response when 
metabolised by either human or rat (Figure 1). Quinidine is 
observ'ed to be a strong inhibitor o f human CYP2D6, while 
quinine, although having no effect on human CYP2D6 metabo­
lism is a strong inhibitor of rat CYP2D enzymes, especially rat 
CYP2D2 (Table 1 and Table 2).
Previous modelling work on Cytochrome P450 has been carried 
out by Levis, see for example [2] and references therein. Recently 
Zhang has published a machine learning model o f species 
selectivity [3] which has a greater than 80% accuracy in predicting 
selectivity. However, models of this kind do not provide 
information on the three dimensional structure of the active sites 
o f the proteins nor the interactions made by the ligands. Similarly, 
there have been many studies that have used quantitative structure 
activity relationships [2] to probe ligand binding but again these 
studies lack 3 dimensional information. MulhoUand et al. [4] have 
used the combined techniques of (QM/MM to study the 
interactions with the iron in GYP, which is the currently highest 
lev'el o f modelling that can be achieved in proteins and have been 
useful in describing the mechanistic details of the catalytic cycle. 
Venhorst et al. [1] have generated homology models based on the 
x-ray structure of rabbit CYP2C5 and used this to identify 22 
active site residues that are o f importance in ligand binding. In this 
work we hav'e based our models on the now available x-ray 
structures of the Human CYP2D6 which is a better starting point 
for the comparison. Computational techniques, such as homology 
modelling and molecular docking can be used to effectiv'ely 
investigate any sequence variation between species. This work 
describes a variety of techniques used to create homology models 
o f rat CYP2D and to investigate the cause o f species selectivity in 
Rat and Human enzymes.
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Quinidine
HO
Quinine
Figure 1. Structures o f the epim ers quinine and quinidine.
doi:10.1371/journal.pone.0063335.g001
Previous work on molecular recognition in antibody:antigen 
interactions concluded that the ability o f antibodies to recognise a 
wide variety o f ligands was not due to specific interactions with 
certain key selected amino acids but rather was due to a range of 
non-specific interactions in the overall active site [5], CYP450’s 
also show this inducible nature where they can also respond to a 
wide variety o f  ligands and one o f our aims in this paper was to see 
if, with ligands that differ only in the arrangement about one chiral 
centre, quinidine and quinine would show specific interactions or 
would also show non-specific binding.
M eth od ology
Homology Models of Rat Cytochrome P450 2D Enzymes
Full length sequences o f human and rat CYPs were taken from 
the UniProt database [6] with a combination o f PSIPred [7], JPred 
[8] and Porter [9] being used to predict the secondary structure of 
the rat CYPs. A  series o f sequence alignments were generated 
using ClustalX [10,11] based on aU known human and rat CYP2D  
sequences (Figure 2). The predicted secondary structure from 
PSIpred, JPred and Porter disagreed at one point with that 
predicted from ClustalX. Hence a manual modification o f the 
sequence alignment was performed to give the best consensus 
match with the highest sequence identity (=«57% between all rat 
CYP2D enzymes and —56% between rat and human CYP2D  
enzymes). The Molecular Operating Environment (MCE) [12] 
was then used to generate 25 high-precision, three-dimensional 
homology models for rat cytochrome P450 2D 1-5 and 2D 18 
enzymes. The models were based on the available human 
CYP2D6 crystal structures both with a ligand bound in the active 
site (PDB entry code 3QM 4 [13]) and without (PDB entry code 
2F9Q^ [14]). Models were generated under both the Amber99 and 
Charmm27 force fields and all relevant crystallographic informa-
Table 1. Experimental IC5 0  values for quinidine and quinine 
in rat and human CYP2D taken from Venhorst et al. [Ij.
IC50/1M
Ligand CYP2D1 CYP2D2 CYP2D3 CYP2D4 CYP2D6
Quinidine 19.9+1.9 2.8±0.7  26.9±4.4  47.2+13.4 0.0033±0.001
Quinine 46.5 ± 7 .6  0.0094±0.009 12.0±0.2 1.7±0.4 0.61 ±0.05
doi:10.1371/journai.pone.0063335.t001
tion was retained. The models formed were analysed both visually 
and statistically within M OE [12].
Molecular Dynamics Studies on Homology Models
M OE [12] was used to perform a series o f molecular dynamics 
(MD) simulations in vacuo to judge the stability and quahty o f the 
homology models generated. The simulations were performed 
using the N PT  ensemble, which holds the number o f atoms, the 
pressure and the temperature constant throughout the simulation 
while allowing volume to vary. This ensemble was chosen as the 
simulations were performed at body temperature and pressure 
which is not normally subject to change in biological systems. 
Simulations were run at both 0 K  and 0 Pa for 2 ps and 310 K  
and 101 Pa for 2 ps.
CYP2D Active Site Studies
Site Finder [15] available within M OE [12] was used to 
generate a series o f possible ligand binding sites within the two 
human CYP2D6 crystal structures, by identifying clusters of 
relevant ‘alpha spheres’ considered to be in solvent accessible 
regions of hydrophobicity and hydrophüicity [16,17]. A  surface 
analysis o f the active sites o f both human GYP2D6 crystal 
structures was performed using the surface mapping tool available 
within M OE [18,19,20] with the active site definitions being taken 
from literature [1] and the Site Finder [15] analysis.
Inhibitor Docking
Quinidine and quinine, which are known inhibitors o f human 
Cytochrome P450 2D6 were docked into both the human 
CYP2D6 crystal structures [13,14] and the rat CYP2D homology 
models using the available M OE docking program. In previous 
work from our group [21] results more consistent with experiment 
have been achieved by docking the x-ray crystal structure o f the 
ligand rather than a model built up on an atom by atom basis. 
Therefore we have docked both the x-ray crystal structure o f 
quinidine [22] and the molecular model o f quinidine and the 
model o f quinine as there is no x-ray structure o f quinine available.
Docking was performed using three methods; an alpha triangle 
rigid-protein-flexible-ligand dock with a force field based refine­
ment step and London AG scoring functions, an alpha triangle 
rigid-protein-rigid-ligand dock with a Gridmin based refinement 
step and London AG scoring function and a manual placement 
and force field based minimisation step. As the force field based 
methods caused some anomalies to occur with the aromatic rings
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Figure 2. Sequence Alignment of Human CYP2D6 and all Rat CYP2D enzym es, a-helices are shown in red, p-sheets in yellow and p-turns in 
blue. The sequence alignment was generated using both ClustalX and the MOE sequence alignment program. 
doi:10.1371/journal.pone.0063335.g002
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Table 2. Experimental and Calculated K| values for quinidine 
and quinine in both crystal structures of human CYP2D6.
E xperim ental C alcu lated
Ligand Ki/nM Kj/pM
Quinidine Crystal Structure 0.03 2 .13x10“  ^ (2F9Q) 
5.07x10"® (3QM4)
Quinidine Molecular Structure 0.03 2.65x10"® (2F9Q) 
2.01 xIO"® (3QM4)
Quinine 5.9 1.41 xIO"® (2F9Q) 
2.77x10"=' (3QM4)
doiil 0.1371 /journal.pone.0063335.t002
of the hgands, the Gridmin based docking method was used as this 
greatly reduced the number of observ ed anomalies in this case. 
The manual placement method was used to see if interaction with 
the Fe atom was possible with these ligands. In practice as these 
ligands are inhibitors and not substrates the Gridmin results were 
taken as less subject to bias on our behalf and none o f these 
dockings showed a close approach to the Fe atom. The difference 
in docking behaviour belween substrates and inhibitors will be the 
subject of the further publication.
For each o f the docks, the following information was recorded 
for each contact made with the protein (more than one in some 
cases):
•  Residue types, number and subunit
•  Bonding type (backbone acceptor/donor, H-bond acceptor/ 
donor (side chain));
Psi
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Figure 3. Ramachandran Plot for a m odel of rat CYP2D1 based  
on 2F9Q.
doi:l 0.1371 /journal.pone.0063335.g003
•  Distance between donor and acceptor as calculated by M OE
(Â);
•  Contact point on the ligand according to the numbering 
scheme.
Figure 4. Quinidine inducibly docked into a m odel of human CYP2D6 based on the 2F9Q crystal structure. Quinidine is shown in
orange inside the active site which is shown in green.
doi:10.1371/journal.pone.0063335.g004
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c
Figure 5. Quinidine inducibly docked into a m odel of human CYP2D6 based on the 3QM4 crystal structure. Quinidine is shown in 
orange inside the active site which is shown in green. 
doi:10.1371/journal.pone.0063335.g005
Ligand Optimisation
In order to correct for the anomalies in aromatic structure 
observed during docking, a ligand optimisation script provided by 
M OE [12] was employed. This script duplicated the docked ligand 
and corrected the confirmation before refining the duplicate on to 
the original confirmation. This step was only required for the 
docks o f quinidine and quinine in the 2F9Q_ based models of 
CYP2D2 and for quinidine in CYP2D5. No such anomalies were 
observ'ed when docking to the 3QM 4 based structures.
Protein-Ligand Binding Analysis
A combination of the 3D ligand interaction prediction and 2D 
ligand interaction tool from M OE were used to predict and 
wsualise protein-ligand interactions likely to occur for each o f the 
bioactive compounds docked.
Calculation of Kj from AG
K; values were calculated for each o f the docked compounds for 
comparison with experimental values (Table 1 and Table 2). K; 
values were calculated from AG using;
\ G = - R T \ n K , .
à G = - R T \ n -K,
(2)
(3 )
(4 )
Induced Docking Model
Owing to the inducible nature o f CYP2D enz}Tues a further 
energy minimisation step was introduced into the docking analysis 
in order to more accurately model enzyme response. After docking 
the protein was minimised under the CH.ARMM27 force field 
[23] which is parameterised for protein simulations around the 
fixed heme and docked ligand providing a representation of the 
induced docking model.
AG =  R T \ n K i
A GKi = eTFT
(5 )
( 6 )
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1
Figure 6. Interaction diagram showing an overlay o f quinidine (green) and quinine (orange) in a) Human 2D6 (2F9Q), b) Rat 2D2 
(2F9Q), c) Human 2D6 (3QM4), d) Rat 2D2 (3QIVI4). The lines shown in green are electrostatic interactions (pi bonding or H bonding). 
doi:10.1371 /journal.pone.0063335.g006
Results and D iscussion
The homology models were analysed by Ramachandran plots 
(Figure 3). This clearly shows that 99% of the residues are in 
allowed conformations and there are no outliers, providing 
confidence in the models used. The x-ray structure o f prinomastat 
bound to Cytochrome P450 2D6 [14] was used to validate the 
docking procedure. The docking results showed that M OE was 
able to reproduce the x-ray structure Mth an rmsd of 0.5592 A 
and that prinomastat was in the wcinity of Ser304 and G lu219. 
There is no interaction in this x-ray structure with Asp301, which 
has been proposed as a vital residue [24]. One of the major 
concerns in cytochrome P450 modelling is the inducibility of the 
active site [25] i.e. if one compares the x-ray structures of the 
native Human 2D6 with the structure with prinomastat bound 
there is a significant difference (increase in volume of 130 A) in the 
active sites. The active site of the ligand bound structure is larger 
but more closed indicating that the protein has conformed to the 
shape of the ligand. Therefore we ha\'e carried out docking to both 
the homology models of the native enzyme and the ligand bound 
models (Figures 4 and 5). Table 3 shows that there are more 
interactions with amino acid residues in all models for those based 
on 2F9Q  rather than 3Q_M4 indicating that the active site is 
smaller as discussed above. Table 3 shows the close approaches
(within 3.8 Â) o f amino acid residues in the rat and human models 
(based on 2F 9Q  and 3QM4) with both quinine and quinidine. 
Figure 6 shows a casual representation o f the interactions 
summarised in Table 3, which makes the data presented easier 
to interpret. In the models based on the 2F 9Q  structure 
interactions with residue 304 occur for all rat and human models 
for both ligands. Residue 213, 216, 244 and 301 are shown to 
interact with both human and rat models in quinidine but not in 
quinine, wiiereas quinine interacts with 308, 374 and 483 in both 
human and rat but not in quinidine. Interactions that occur in 
both human and rat models indicate similar modes o f binding in 
both models. There are ten interactions with the Human 2D6 
model in quinidine but only seven in quinine. O f these only four 
are common, i.e. those with 217, 220, 304 and 373. In the models 
based on 3QNI4, residues 216, 244, 301, 304 and 309 show 
interactions with both ligands in both human and rat structures 
with almost all rat and human models showing interactions with 
301 for both ligands. There are ten observed interactions with 
quinidine and nine with quinine in the human structure. O f these 
interactions seven are common including residues 117, 216, 244, 
301, 304, 309 and 484. Previous work on the docking of quinine 
and quinidine using the models based on the rabbit x-ray structure 
[1] indicated the quinidine interacted with Asp301, Ser304 and 
Phe 120 in the human model and couldn’t approach A sp301 as
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Table 3. Amino acid residue interactions with Quinidine and Quinine in models based on both crystal structures.
Ligand 2F9Q 3Q M 4
Residue
Number Q u in id in e Q u in in e Q u in id in e Q u in in e
5 4 2D18
107 2D2, 2D3 (jt) 2D2 (Tt)
11 0 2D2
1 12 2D2, 2D3 2D2
117 2D6, 2D6 (jt) 2D6 (Tt)
12 0 2D6 2D1 ( i t ) ,  2D2 (Tt) 2D1, 2D4, 2D4 (T t), 2D18, 2D18 (Tt)
121 2D3, 2D4 2D18 2D2 2D2, 2D3, 2D18
2 0 8 2D6
2 0 9 2D6
2 1 2 2D3
2 1 3 2D2, 2D3 (jr), 2D6, 2D18 2D1, 2D3, 2D4, 2D5, 2D5 (tc) 2D3
2 1 6 2D2, 2D3, 2D6 2D1, 2D2, 2D3 2D1, 2D2, 2D4, 2D5, 2D6, 2D18 2D2, 2D4, 2D5, 2D6, 2D18
2 1 7 2D2, 2D3, 2D4, 2D6 2D3, 2D5, 2D6, 2D18
2 2 0 2D2, 2D3, 2D4, 2D6, 2D18 2D2, 2D6, 2D18, 2D18 (rt)
2 4 4 2D1, 2D5, 2D6 2D3 2D1, 2D3, 2D6 2D1, 2D2, 2D5, 2D6, 2D18
2 4 8 2D2
2 9 7 2D2, 2D4 2D3. 2D4
3 0 0 2D5 2D3 2D1, 2D4, 2D18 2D1. 2D2, 2D3, 2D4, 2D5, 2D6, 2D18
301 2D1, 2D2, 2D6 2D1, 2D2, 2D3 2D1, 2D2, 2D3, 2D4, 2D5, 2D6, 2D18 2D1. 2D3, 204, 205, 206, 2018
3 0 4 2D1, 2D2, 2D3, 2D4, 2D5, 
2D6, 2D18
2D1, 2D2, 2D3, 2D4, 2D5, 2D6, 
2D18
2D2, 2D4, 2D6, 2D18 201,202,204,206,2018
3 0 5 2D3, 2D4, 2D18 2D2, 2D3. 2D18 2D2, 2D4 201, 202, 203, 204, 2018
3 0 8 2D2, 2D18 2D3, 2D5. 2D6, 2D18 2D18 206
3 0 9 2D1, 2D2, 2D3 2D1, 2D3, 2D4 2D1, 2D5, 2D5 203, 206
3 6 9 2D1
3 7 0 2D2, 2D18 2D2, 2D4 2D3. 2D5
3 7 2 2D18 2D4, 2D18
37 3 2D1, 2D2, 2D4, 2D5, 
2D5, 2D18
2D1, 2D4, 2D6, 2D18 2D5, 2D18 201, 203, 2018
3 7 4 2D1, 2D1 ( J t) ,  2D2, 2D3, 2D18 2D2, 2D3, 2D6, 2D18 (jt) 201, 205
3 7 5 2D4
4 8 2 2D18
4 8 3 2D3, 2D4, 2D5, 2D18 2D1, 2D4, 2D5, 2D5, 2D18 2D5 201, 202 (T t), 2018
4 8 4 2D1, 2D5, 2D18 ( tt) 2D3, 2D4, 2D5 2D5, 2D18 206
doi:10.1371 /journai.pone.0G53335.t003
closely in the Rat 2D2 model but formed a hydrogen bond to the 
main chain o f Met304 (replaces Ser304 in 2D2). In this work, 
interactions between 2D2 and Asp301 are found with models 
based on 2F 9Q  showing a movement o f the Met304 side chain 
during the energy minimisation step to allow for interaction 
between quinidine and AspSOl. For those models based on 3QM 4 
the M et304 side chain is already in a position which allows for 
interaction with Asp301. In the previous work on the quinine 
docking [1], interactions were found to the carbonyl backbone o f  
301 in the human model and to Asp216, T hr217 and M et304 in 
the rat 2D2 model. Interactions were found to backbone and side 
chain of AspSOl in the 3QM 4 and 2F9Q, human structures 
respectively, but neither Asp216 nor M et304 interactions were 
observed for rat 2D2.Experimental binding data for Human 2D6 
(Table 1 and Table 2) shows quinine binds approximately 1000
times less well than quinidine. In both the 2F9Q,and 3Q M 4 based 
models o f human 2D6, more interactions were observed for 
quinidine than quinine. However, the experimental binding 
situation is reversed in the Rat 2D2 where quinine binds 
approximately 1000 times tighter than quinidine. Here the 
quinine should make more contacts with the protein. This is seen 
in the 3QM 4 model where ten contacts are observed for quinine 
while quinidine has only nine. In fact these results follow the 
experimental data in most cases with more interactions being 
observed for the more potent epimer for all but the 2F9Q^ based 
model o f 2D2 and the 3QM 4 based model o f 2D1. If the lowest 
energy docking results are considered (Table 4), in the models 
based on the 2F 9Q  structure for the 2D2 case the quinine has a 
lower free energy o f binding than the quinidine model structure, 
— 11.68 to —9.8 K cal/m ol. The results are reversed when the
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Table 4. AGbmding energies calculated from docking simulations to CYP2D2 and CYP2D6 models.
Ligand 2F9Q
CYP2D2 CYP2D6
E (kcai/m ol) Ki LogKi E (kcal/m oi) Ki LogKi
Quinidine Crystal Structure 
Quinidine Molecular Structure 
Quinine
-13 .8513
-9 .8005
-11 .6875
6.93826E-11
6.48885E-08
2.68049E-09
-10.1587492
-7 .187832299
-8 .571786133
-13 .3215
-1 0 .4836
-1 0 .9 8 6 7
1.69752E-10
2.04726E-08
8.75369E-09
-9 .770186008
-7 .688827987
-8.057809001
3Q M 4
CYP2D2 CYP2D6
E fkcal/m oi) Ki LogKi E (kcai/m ol) Ki LogKi
Quinidine Crystal Structure 
Quinidine Molecular Structure 
Quinine
-11 .3477
-11 .3599
-1 0 .4934
4.75804E-09
4.58296E-09
2.01365E-08
-8 .322571765
-8 .338853574
-7 .696015453
-1 2 .0 4 7
-11 .2423
-1 1 .0223
1.46067E-09 
5.685E-09 
8.24293E-09
-8 .835448774
-8 .245269839
-8 .08391857
doi:10.1371 /journal.pone.0063335.t004
quinidine x-ray structure is compared to the quinine model 
structure, indicating that there is no advantage in using the x-ray 
structure in this case. In the 2D6 model based on 2F9Q, it is the 
quinidine model that has the lowest binding free energy. This is 
consistent with the experimental results. For the models based on 
the 3QM 4 structure the quinidine (X-ray or model structure) has a 
lower free energy o f binding than the quinine in all cases. This is 
only consistent with experiment for the 2D6 case, so these results 
cannot explain the difference observed in the 2D2 case. Therefore, 
in the case o f simulated binding free energies, the models based on 
the open active site are more consistent with experiment. In the 
previous work [1], the differences in binding efficiency between 
the epimers were ascribed to the difference in close approach to 
the iron atom in the heme. However, it was stated that the ligands 
were located close to the heme in this work but that this was not a 
requirement for aU competitive inhibitors, like these ligands, and 
multiple binding modes are possible. These large differences in 
experimental binding efficiency cannot be prescribed wholly to 
small differences in interaction energies, so as in the antibody:anti- 
gen case, it is the sum total o f the weak interactions overall that 
account for the inducible nature o f CYP450 binding and this is 
true in the quninerquinidine case also. The large non-specific 
binding site o f GYP450 is ideally suited to binding a wide variety 
o f ligands.
In ligands with polar groups prominent there is an interaction 
observed with the iron o f the Heme in the protein. This is 
consistent with the x-ray results for prinomastat which shows a Fe- 
N  interaction with the pyridinyl ring. However, we do not observe 
a close approach to the iron in our docking studies. This may
suggest that as both quinine and quinidine are inhibitors (at least 
in vitro [26]), their roles are to occupy space in the binding site 
thereby denying other ligands access to the active site.
Conclusions
The basis o f species selectivity in human and rat cytochromes is 
a complex problem, which demonstrates clearly how non-specific 
binding can be used in nature to ‘engineer’ proteins that are able 
to bind to a wide variety o f substrates. An induced fit minimisation 
step is shown to be useful in reproducing experimental docking 
results. Hence models based on the larger closed active site in the 
3QM 4 structure are better models o f the observed experimental 
data for quinidine and quinine than those based on the more open 
2F9Q, and that there are differences in both the number o f  
interactions made by different ligands as well as their close 
approaches and it is important to take this into account when 
seeking to understand their binding. In all o f the rat models 
studied this is true apart from 2D1 where the 2F9Q,model is better 
at reproducing the experimental binding data.
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